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Summary
Gastric cancer is a common cause of cancer death in the world. The mortality rate 
from gastric cancer is high in UK as it often presents late, often with local or distant 
metastasis. This makes the treatment options limited. The pathogenesis of gastric cancer 
occurs in a multi step pathway with pre cancerous conditions leading to cancer eventually. It 
is important to understand this carcinogenic process (aneuploidy and abnormal gene 
expression levels) and the driving forces (eg. Helicobacter Pylori infection) which will enable 
us to alter the disease outcome.
This series of experiment included cytogenetic investigation which involved obtaining 
gastric cells using brush cytology and using Fluorescent insitu hybridisation technique to look 
for aneuploidy levels of chromosome 1 and 4. These two chromosomes were chosen as 
chromosome 1 has been recently shown to be abnormal in early in premalignant stages of 
gastric cancer. Chromosome 4 was chosen as hyperploidy of chromosome 4 was the 
predominant chromosomal aberration in Barrett’s oesophagus. This study has shown that the 
aneuploidy level of chromosome 1 progressively increased with the progression of the 
histological stages according to the Correa’s premalignant gastric cancer pathway. Significant 
increase in aneuploidy levels of chromosome 1 was seen in H. Pylori associated gastritis, 
implying that H. Pylori play a very important role in the progression of the disease.
Aneuploidy can occur due to various genetic defects that may potentially occur during 
mitosis. Spindle cell check points play a vital role in preventing the cells from proceeding to 
the anaphase stage if there is any defect in the kinetochore attachment. Certain genes like 
MAD2 and BUB1 are thought to be instrumental in controlling the spindle cell check points 
and it is believed a steady state of genes like MAD2 and BUB1 are required for this. In the 
second part of this study, the MAD2 and BUB1 expression levels were measured and 
correlated to the aneuploidy stages. There was no significant difference in their expression 
levels in patients with significant aneuploidy level. MAD2 levels were increased in H .Pylori 
associated gastritis, which implies that H. Pylori plays an important role in the pathogenesis 
of gastric cancer.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 Gastric cancer
Gastric cancer is one of the leading causes of cancer-related deaths worldwide 
(Parkin et al 2005) and is the fourth most common cause of death in Europe (Ferlay et al 
2010) as it is often diagnosed at an advanced stage when patients present with 
symptoms like abdominal pain, vomiting, weight loss or gastrointestinal bleeding or 
anaemia. When diagnosed at an advanced stage, it is usually incurable. The 
effectiveness of treatment regimen like surgery, chemotherapy and radiotherapy are 
limited by advanced local disease and metastatic spread. In fact, only 55-65% of gastric 
cancers are surgically amenable to resection at diagnosis (Keighley 2003).While the 5 
year survival of patients with advanced gastric cancer is only approximately 20%, early 
tumour resection can achieve 5 year survival rates of 90% (Karpeh et al 2001). In the 
United Kingdom, the 5 year survival rate from gastric cancer has tripled but is low at 
15%. In the United Kingdom, most patients are diagnosed with advanced disease often 
with lymph node metastasis; their survival rate is less than 5% (Cancer Research UK 
2010). Other countries in Europe have similar 5 year survival rates, but the rates have 
increased in Spain and Austria (Keighley 2003). However, very good results can be 
achieved if the disease is diagnosed at an earlier stage (small tumours of less than 5cms, 
no serosal invasion or lymph node metastasis). The 5 year survival rate of patients 
diagnosed with earlier disease is greater than 80% and therefore the challenge is to 
increase the patients diagnosed with early disease (Cancer Research UK 2010).
In Japan, there is high disease prevalence and also a surveillance program to 
detect early cancers, their 5 year survival rate is more than 90% (Bowles, Benjamin 
2001).
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1.2 Cellular composition of gastric and oesophageal mucosa
1.2.1 Oesophagus -  Anatomy and Histology
The oesophagus acts as a conduit for the transport of food from the mouth to the 
stomach.lt is 18-26cms muscular hollow tube with an inner skin like lining of stratified 
squamous epithelium. Structurally, it consists of innermost mucosa, submucosa, 
muscularis propria and outermost adventia. On Endoscopy, the mucosa appears smooth 
and pink. The oesophagogastric junction can be recognized by the presence of an 
irregular Z line, demarcating the difference between the light oesophageal mucosa and 
the dark red gastric mucosa. This multilayered epithelium consists of three functionally 
distinct layers: stratum comeum, stratum spinosum, and stratum germinativum. The 
most lumen oriented stratum comeum acts as a permeability barrier between the lumen 
content and blood. The middle layer of startum spinosum consists mainly of 
metabolically active spiny cells. This spiny shape is due to the numerous desmosomes 
connecting cells throughout the layer. This desmosomal network maintains the 
structural integrity of the tissue. The basal layers of stratum germinatum contain 
cuboidal cells that occupy 10% to 15% of the epithelium’s thickness and are uniquely 
capable of replication. The oesophageal epithelium contains a number of other cell 
types including aryrophillic endocrine cells, melanocytes, lymphocytes, Langerhans 
cells (macrophages), and eosinophils.
Below the epilthelium is the lamina propria, a loose network of connective tissue 
within which blood vessels and scattered lymphocytes, macrophages, and plasma cells 
are present. The lamina propria protrudes into the epithelium to form dermal papillae. 
Normally, this protrudes to less than 50% of the thickness of the epithelium; when 
greater, it is a recognized marker of gastro oesophageal reflux. The muscularis mucosa 
is a thin layer of smooth muscle that separates the lamina propria above from the 
submucosa.
The submucosa comprises dense network of connective tissue within which are 
blood vessels, lymphatic channels, Meissners plexus, and oesophageal glands. The 
oesophageal glands produce and secrete a lubricant, mucus, and factors such as
2
bicarbonate and epidermal growth factor that are important for epithelial defense and 
repair.
The muscularis propria is responsible for carrying out transport function. The 
upper 5% to 33% are composed o f  exclusively o f  skeletal muscle and the distal 33% are 
composed of smooth muscle. In between there is a mixture o f  both skeletal and smooth 
muscle fibres (fig 1.1).
Figure 1.1 Histology o f  the oesophagus
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Figure 1.1. shows the innermost lining o f  the oesophagus, which is made up o f  
squamous epithelium. Below this are mucosa, submucosa and the muscular layer. The 
muscular layer cosists o f  circular and longitudunal muscle fibres. 
www.lecannbiculteur.free.fr.
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1.2.2 Stomach -  Anatomy and cellular composition
The stomach is a J shaped most distensible organ in the body. It receives food 
mixed with saliva and softened by saliva and acts as a reservoir to store large quantities 
of recently ingested food. The stomach volume ranges from about 30mL in the newborn 
to 1.5 to 2.0L in adults. The stomach is divided into four regions, which can be defined 
anatomical or histological landmarks. The cardia of the stomach is the small, ill defined 
area of the stomach immediately adjacent to the gastro oesophageal. The cardia is the 
most fixed region of the stomach. The fundus projects upward, above the cardia and the 
gastro oesophageal junction. The dome shaped area of the stomach is the most superior 
portion of the stomach. The body, or the corpus, is located immediately below and is 
continuous with the fundus. The incisura angularis, a fixed sharp indendation two thirds 
of the distance down the lesser curve, marks the lower end of the gastric body. The 
gastric antrum extends from the indistinct border with the body to the junction of 
pylorus with the duodenum. The pylorus is a tubular structure joining the duodenum to 
the stomach and contains circular muscle fibres, the pyloric sphincter.
The luminal surface of the gastric wall forms thick, longitudinally oriented folds 
or rugae, which flatten on distension. The gastric wall mucosa has four layers: mucosa, 
submucosa, muscularis mucosa, and serosa. Mucosa lines the gastric lumen as a smooth 
velvety lining. The mucosa of the cardia, antrum, and pylorus are somewhat paler than 
that of the fundus and the body. The functional secretory elements are located within the 
mucosal layer. The submucosa, which is located just beneath the mucosa contains the 
collagen and elastic fibres which forms the connective tissue skeleton. The submucosal 
layer also contains lymphocytes, plasma cells, arterioles, venules and lymphatics. The 
third layer is mucularis mucosa consists of: inner oblique muscle, middle circular fibres, 
and outer longitudinal fibres. The final layer of the stomach is the transparent serosa, a 
continuation of the viseral peritoneum (Figure 1.2)
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Figure 1.2 Anatomy of the stomach
Short gastric 
arteries
>y Greater 
curvature
STOMACH ANATOMY
Celtic trunk 
Common
R. gastroepiploic 
artery
FOR SAMPLE USE ONLY = 2008 TRIALSIGHT MEDICAL MEOIA
fsophagus
R. gastric 
artery
I. gastroepiploic 
artery
Lessor
curvature
Py loric sphincter
Figure 1.2 shows the internal and external appearance o f  the stomach along with its 
blood supply, www.trialsightmedia.com
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1.3. Incidence of Gastric cancer
Gastric cancer is regarded as the fourth most common cancer worldwide and 
there are 934,000 (8.4% of all cancers) incident cases worldwide in the world each year 
(Parkin et al. 2005). The incidence of gastric varies depending on the geographical 
location. Almost two thirds of the cases occur in developing world. In China, gastric 
cancer is the commonest cancer diagnosed and account for 38 % of gastric cancer 
worldwide (Parkin et al 2005). It is characterised by wide international variation -  the 
high risk areas are East Asia (China/Japan), Eastern Europe, part of South and Central 
America and the low risk areas are Southern Asia, North America, North and East 
Africa. In the United Kingdom, the crude incidence rate per 100,000 Population is 
12.7% (Cancer Research UK 2010). In the United Kingdom, the incidence of gastric 
cancers increases with age with less than 8% of cases detected before 55years but the 
incidence increases steeply with age.
Gastric cancer is one of the main causes of death associated with cancers 
worldwide and is responsible for 699,000 deaths (Parkin et al 2005).In the United 
Kingdom, gastric cancers are the seventh most common cause of cancer deaths and the 
mortality rates have fallen by around 70% over the last 30 years. Throughout the world 
the gastric cancer mortality has been falling over the last few decades. This has 
happened at different time period in different countries.
In the United Kingdom and the USA, the mortality rate started to decline in 
1930’s while in Japan the rates were continuing to rise until 1950’s and then began to 
decline. In Poland and other European countries the peak was reached in 1960’s and 
into the 1970’s in Portugal. This happened without any significant improvement in the 
diagnosis or the treatment. This is thought to be the modification of effect of the risk 
factors involved with the pathogenesis of gastric cancers.
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1.4. Aetiology of gastric cancer
The aetiology of gastric cancer is multi factorial. Host genetics and 
environmental factors have been implicated in the pathogenesis of gastric cancers.
1.4.1 Family history
Family history is associated with increased risk of gastric cancers (Nagase et al 
1996,Correa 1988, Bernini et al 2006) and with increased risk of precancerous 
abnormalities (Cameiro et al 2004). A recent study has highlighted the increased risk of 
gastric cancer among siblings with gastric cancer (Bakir et al 2000).A recent study has 
looked at the incidence of gastric cancers in patients with relatives with digestive 
system cancers and reported an increase in the risk of both cardiac and non cardiac 
type gastric cancers (Dhillon et al 2001) . A recent study from Sweden has shown an 
increased risk in the sibling of gastric cancer patients ( Altieri,Hemminki 2007).
El- Omar et al (2000) have shown that the relatives of patients with gastric 
cancers have increase prevalence of precancerous gastric lesions, although this was 
more common in patients with Helicobacter pylori infection. The family clustering of 
gastric cancer may be due to a combination of genetic and also due to other 
environmental factors such as H. pylori infection and diet.
1.4.2 Helicobacter pylori
Helicobacter pylori is a Gram negative bacilli, which is known to inhabit the 
human host(Fig 1.3) In 1984, Warren and Marshall described this spiral bacterium that 
is similar to Campylobacter, in the mucosa of patients with chronic gastritis. 
Helicobacter pylori was declared a class 1 carcinogen in 1994 due to its association with 
gastric cancer (IARC 1994) and, because of the available epidemiological and 
experimental evidence is considered to be a major epidemiological factor in gastric 
carcinogenesis. Other bacteriae have been implicated in the pathogenesis of gastric 
cancer for e g., Helicobacter heilmanii and Mycoplasma infection but their correlation is
7
Figure 1.3 H.pylori
AUTHOR: STEFANO TARTAROTTI
Figure 1.3 shows the eletron microscopic picture o f  H. pylori, which is a spiral like 
bacterium with multiple flagellae. www.fallingpixel.com
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weak (Stadtlander ,Waterbor 1999). There are studies which looked at other infectious 
cause (viral, fungal and parasitic) for gastric cancer. Epbstein-Barr viral infection, 
which is a recognised human carcinogen implicated in the development of other cancers 
like Hodgkins’s disease and Naso sinal carcinoma (IARC 1997), is one of the infections 
which has been implicated in the gastric carcinogenesis (Stadtlander, Waterbor 1999).
The prevalence of H. pylori worldwide has been estimated at 50% but they vary 
depending on the geographic location (Nepomnayshy, Birkett 2000) . A recent review 
has shown the variation in the prevalence of H. pylori with the prevalence rate in Japan 
(4%) and an African village (82%) (Bruce, Maaroos 2008). H. pylori is transmitted 
through faecal oral route and the high rates of infectivity could be secondary to large 
family units and poor hygiene. Infection occurs in early childhood and re infection is 
rare after eradication in adults, although this is not always the case in the developing 
world (Logan, Walker 2001).
Asymptomatic H. pylori infection is common and only 20% of the infected 
individuals develop clinical disease (Uemura et al. 1997). H. pylori is associated with 
superficial gastritis, chronic gastritis and intestinal metaplasia (Bomschein et al 2010) 
and all these changes are found in the premalignant stages of gastric carcinogenesis 
(Correa 1988). The site of the infection plays an important role in determining the type 
of disease. Infection of the corpus can lead to acute pan gastritis and result in mild 
gastritis with no upset in gastric acid secretion and the patient will remain 
asymptomatic. On the other hand, chronic infection with H. pylori causes loss of acid 
secreting cells, hypochlorhydria, bacterial overgrowth and increased risk of gastric ulcer 
and gastric cancer. A similar effect is seen in patients with autoimmune pangastritis 
(pernicious anaemia) resulting in hypochlorhydria and resulting in the increase in the 
risk of gastric cancer (Faraji, Frank 2002). H. pylori infection of the antrum leads to 
antral gastritis with intact acid secreting corpus and results in increased parietal cell 
mass leading to increased acid secretion due to dysregulation of feedback pathway 
controlled by gastrin produced in the antrum. This leads to high incidence of duodenal 
pyloric metaplasia, which are colonised by H. pylori and may result in duodenal 
ulceration (Logan, Walker 2001,Faraji, Frank 2002).
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Chronic infection with H. pylori triggers host immune response, which may not 
be strong enough to clear the infection. Similarly, concurrent infection with different 
strains of H. pylori result in DNA exchange between the strains and result in more 
virulent strains(Logan , Walker 2001). A number of virulence factors are described in
H. pylori and can be divided into colonisation factors and disease associated factor. 
Almost all strains express colonisation factors, which help them in colonising the gastric 
mucosa but only certain strains of H. pylori has disease associated factors. The two 
major virulence factors are the vacoulating cytotoxin (Vac A) and the cytotoxin 
associated protein (Cag A) (Dundon et al 2001)
The majority of gastric adenocarcinoma is thought to be the result of chronic
H. pylori infection. The development of adenocarcinoma is a result of the multistep 
process of mucosal alterations varying from gastritis, intestinal metaplasia and 
eventually invasive carcinoma is well recognised.
Recent studies focus on detecting the “point of no return”, which is defined as 
alterations that are no longer reversed by treating and eradicating the H. pylori infection 
and thereby the progression to gastric cancer is not altered. H. pylori infection not 
only alters the immune response but also induces genetic alterations. It is important to 
identify these genetic alterations as this would help us in identifying the risk factors 
involved in the development of gastric cancer. The detection of high risk individuals 
who are at risk of developing gastric cancers would help us in designing appropriative 
preventative and treatment strategies (Bomshein J et al 2010).
There are number of invasive and non invasive methods to determine the 
infection of H. pylori. The most commonly used method is the Urea Breath test. This is 
based on the fact that the bacteria produces urease enzyme. An ingested solution of 
urea, labelled with Carbon 13, is rapidly hydrolysed by the H. pylori urease enzyme and 
the resulting carbon dioxide, which is absorbed through the gastric mucosa and into the 
systemic circulation. This is then released in the expired gas. It detects current infection 
and is useful in assessing the eradication of H. pylori after treatment. Faecal antigen test 
is available to detect H. pylori is useful in detecting infection present after treatment
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(Manes et al. 2001,Vaira et al. 2000).Serological testing of H. pylori antibodies relies 
upon detecting IgG and IgA antibodies and ELISA is used to detect this. This method is 
reasonable sensitivity and is used for global screening purpose. The antibody level is 
known to decrease slowly after the treatment and is not a reliable indicator of 
eradication or re-infection. Invasive detection of H. pylori involves detection of the 
organism in gastric biopsy. This is considered to be a gold standard test for the detection 
of H. pylori. But the major disadvantage with this is that it requires an upper GI 
endoscopy, which is a test associated with complication such as perforation and 
bleeding. Again it is noted that previous treatment with proton pump inhibitors results 
in alteration of gastric pH and decrease the detection rate of H. pylori. Sampling error is 
common and up to 14% of infected patients do not have H. pylori on the biopsy 
analysed especially in patients with gastric atrophy, intestinal metaplasia and bile reflux 
(Logan, Walker 2001). Multiple biopsies and multiple sites of gastric biopsies would 
result in decrease in the sampling error but this is in time and labour intensive. A 
method of H. pylori detection by passing the need for histological detection would be a 
CLO test (Delta West Ltd., Bentley, Australia), whereby the urease activity of H. pylori 
is detected by a change in colour in a pre packaged agar gel of phenol red and urea. This 
is readable in the endoscopy unit and is widely available (O’connor, Sebastian S 
2003).The sensitivity of CLO test decreases in bleeding (Figure 1.4)
Treatment of H. pylori involves a combination of an acid suppressor (proton 
pump inhibitor, H2 receptor antagonist or bismuth) and two antibiotics (amoxicillin/ 
clarithromycin, metronidazole/clarithromycin or amoxicillin/metronidazole) is a popular 
and effective therapy, with eradication rate of 90% (Unge 1998). Quadruple therapy 
using bismuth is recommended if  the first line treatment (Hojo et al. 2001). Successful 
eradication of H. pylori leads to peptic ulcer healing and results in decrease in ulcer 
recurrence. Eradication is recommended in first degree relatives of patients of gastric 
cancers, patients with atrophic gastritis, patients with gastro duodenal diseases with 
peptic ulcer, low grade dysplasia, mucosa associated with lymphoid tissue[MALT] ,iron 
deficiency anaemia and chronic idiopathic thrombocytopenia purpura 
(Malfertheiner,2007)
11
Figure 1.4 CLO test for H.pylori detection
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Figure 1.4 A Sample o f  CLO test, the kit is opened and a gastric biopsy specimen is 
placed in a well filled with an agarose gel and urea.The second picture shows the CLO 
test kit before the gastric biopsy is placed and the pink well demonstrates that the 
specimen is CLO positive, implying that the patient is infected with H. pylori.
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1.4.3 Smoking
Smoking increases the risk of developing gastric cancers. Smoking is 
particularly a strong risk factor in men (Chung et al. 2010, Aragones et al. 2009). It has 
also been noted that that the effect of smoking in gastric cancer development is dose 
related and high incidence of gastric cancers in heavy smokers (Koizumi et al. 2004).
1.4.4 Socio economic factors
Both socioeconomic and geographic differences influence the incidence of 
gastric cancers. Gastric cancer incidence is high in developing world when compared 
with the developed world (Stadtlander, Waterbor 1999, Parkin 2005). There is 
difference in the incidence within the same country (Aragones et al. 2009).
1.4.5 Diet
Epidemiological and experimental studies have shown that certain food can be 
protective against gastric carcinogenesis, and include fruits (especially containing 
ascorbic acid) and vegetables. Nitrosamines and salt, alcohol are implicated with 
increase in the rates of gastric cancers (Tsugane,Sasazuki 2007, Wang et al. 2009, Moy 
et al 2010). The countries with high incidence of gastric cancers have high salt intake 
and restriction of salt intake is advocated as a prevention strategy (Tsugane, Sasazuki 
2007).
1.4.6 Sex difference
The incidence of gastric cancer increases in men after the third decade, but the
incidence in females only starts to increase after the sixth decade (Sipponen et al 2002).
The incidence of gastric cancer in males to females is 2:1 and this cannot be entirely
attributed to the environmental risk factors. It is implicated that oestrogen may have a
protective role in the pathogenesis of gastric cancer. Those with longer fertility and on
hormone replacement are found to have lower gastric cancer incidence, whereas use of
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tamoxifen is associated with increased gastric cancer incidence. Similarly men with 
prostate cancers treated with oestrogen are found to have lower incidence of gastric 
cancer (Chandanos et al 2008).
There is a significant overlap between the various aetiological factors discussed 
above in determining the effect of individual risk factors in the development of gastric 
cancer.
1.5. Classification of gastric cancer
Gastric cancers can be classified by different methods. Anatomically, they can 
be classified depending on the site of the cancer. Distal gastric cancers used to be the 
most common form of gastric cancer but their incidence has been slowly diminishing in 
the Western countries and increasing incidence of proximal gastric cancers are noted 
(Grady 2001). The decrease in the incidence may reflect the improvements in lifestyle 
and the socio -  economic conditions in western population. Proximal gastric cancers of 
the cardia are not always distinguishable from the oesophageal adenocarcinomas and 
the presentation is usually at an advanced stage of the disease and a collective term of 
gastro -oesophageal cancer is used.
Gastric cancers can be classified based on the cell of origin and the histological 
pattern. Ninety percent of the gastric tumours are adenocarcinomas, lymphomas, 
carcinoid tumours and leiomyosarcomas accounting for the rest.
Adenocarcinomas are classified into two main types based on their histological pattern- 
better differentiated intestinal-type adenocarcinoma and the poorly differentiated diffuse 
-type (Lauren 1965). A more recent classification is based on mucin expression and 
classifies gastric cancer in to 4 different sub groups: the gastric or foveolar type (G 
type), the intestinal type (I- type), the gastric and intestinal mixed type (GI -  type) and 
the neither gastric or foveolar type (N-type) ( Tatematsu et al. 1990) .Distinct genetic 
changes appear to be associated with distinct phenotypes. In I-type gastric cancer, p53 
mutations and allelic deletions of the adenomatous polyposis coli (APC) gene are 
observed frequently than in G type adenocarcinomas. Microsatellite instability (MSI) is
15
found more often in G -  type adenocarcinoma than in I-type adenocarcinoma (Endoh et 
al. 2000, Shibata et al. 2003).
1.6. Familial gastric cancers
Hereditary diffuse gastric cancers account for approximately 1-3% of the gastric 
cancers and they are caused by a germ line mutation of CDH1 gene, which encodes E- 
cadherin, a molecule central in the process of development, cell differentiation and 
maintenance of epithelial architecture (Grunwald 1993). Gastric cancers in its hereditary 
form can be caused by germ line mutation of TP- 53 tumour suppressor gene which 
occurs in Li- Fraumeni syndrome (Oliviera et al 2004, 2009). BRCA2 gene mutations 
are associated with not only breast carcinomas but also gastric, ovarian, pancreatic and 
pancreatic cancers (The Breast Cancer Link -age Consortium 1999, Jakubowska et al
2002). A proportion of hereditary on polyposis colorectal (HNPCC) is also associated 
with high frequency of extra colonic carcinomas, most commonly associated with 
gastric and endometrium cancers (Lynch et al. 1996) and has microsatellite 
instability(Peltomaki et al 1993). Thirty to forty percent of all HDGC families carry 
CDH1 gene mutations (Oliveira et al. 2009). The gastric mucosa in CHI germ line 
mutation carriers is normal until the second CDH1 allele is inactivated in multiple cells 
in the gastric mucosa, accounting for the multifocal tumour lesion (Cameiro et al 2004). 
It is not exactly clear of the role H. pylori infection plays in the pathogenesis of the 
diffuse gastric cancer in patients with CDH1 mutation. It is possible that the infection 
with H. pylori as well as the dietary and other environmental factors influences the 
disease risk of the susceptible individuals (McColl et al 2002).
1.7 Multistep pathway of gastric carcinogenesis
The exact pathway leading to gastric cancer from normal gastric mucosa is 
unknown. Correa proposed a multistep pathway to intestinal cancer, including the 
precancerous stages and the possible environmental insults that could contribute in the 
pathogenesis of cancer (see figure 1.5)
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Figure 1.5 Correa hypothesis o f  gastric cancer aetiology (Correa 1988)
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High pH (Hypochlorhydria)
Atrophic Gastritis
Fig 1.5.The premalignant stages o f  gastric cancer and its potential contributing factors 
as described by Correa
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Gastritis is an inflammation of the gastric tissue and this could be acute or chronic. 
Gastric atrophy occurs as a result of prolonged ulceration or inflammatory process. 
Intestinal metaplasia represents a non- neoplastic change in the cell and is usually due to 
the sustained adverse environment, and is caused by alteration of the stem cell lineage 
or epigenetic changes. This can be associated with increased cancer risk (Morson et al. 
1980). Intestinal metaplasia is common but gastric cancer is not. Intestinal metaplasia 
may progress from small bowel metaplasia to colonic metaplsia and can be divided into 
3 types -  complete (small intestine type containing goblet, Paneth, endocrine and brush 
bordered cells -enterocytes ), incomplete -  (goblet cell metaplasia) containing goblet 
and mucous cell, no enterocytes, plus sialomucins, incomplete (colonic type) -  
containing goblet and mucous cells, no enterocytes, plus sulphomucins(Correa 1988). 
Dysplasia is the term used to describe cells that has the potential to progress to cancer 
(Grunwald 1993, Morson et al. 1980). Dysplastic cells have enlarged hyperchromatic 
nuclei with coarse chromatin and irregular nucleoli. These features suggest that there is 
failure of cells to mature as they migrate from the stem cell compartment.
1.8 Cancer initiation
Cells are continuously exposed to potential mutagenic agents through their 
exposure to environmental carcinogens or due to their normal metabolism. This results 
in constant genetic alterations within the cells, but stringent monitoring within the cells 
ensures that this damage is repaired before it is transmitted to the daughter cells. If the 
genetic alteration is beyond repair, it results in the cell death (apoptosis). The first step 
in the cancer pathogenesis is the interaction between the cell DNA and the carcinogen, 
which results in a cell with altered cell genome- this process is described as cancer 
initiation. The genetic alteration could occur as a result of exogenous stimulus for Eg., 
chemical carcinogens, oncogenic viruses, exposure to radiation or due to endogenous 
stimulus Eg., oxygen free radicals formed as a result of normal metabolism.
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1.9 Cancer Progression
Carcinogenesis is multistep progress that involves accumulation of genetic changes 
that progressively transform normal cells (Vogelstein et al 1993).Once the cancer 
initiation occurs, the subsequent cells resulting from the mitosis becomes increasingly 
abnormal and develop into cancer. This is cancer progression. Hanahan and Weinberg 
(2000) suggested six possible mechanisms in cell physiology that could result in cancer 
progression
1. Self sufficiency in growth signals (production of their growth signals allows 
these cells to dissociate from their normal micro environmental control 
mechanisms)
2. Insensitivity to growth inhibitory signals.
3. Evasion of apoptysis
4. Maintenance of telomere length which results in limitless replicative potential
5. Sustained angiogenesis ( new vessel formation ensures oxygen supply and 
nutrients to the growing tumour)
6. Capacity to invade tissue resulting in metastasis, responsible for distant spread.
1.10 Clonal evolution
During cancer initiation, a genetic alteration in a single cell gives this cell a 
significant growth advantage, which allows it to proliferate and overgrow its neighbours 
producing a homologous clone. Further mutations occur within this clone as a result of 
genetic instability. Sporadically, one cell may develop additional survival advantage 
and result in a dominant sub -population with the original clone. In 1976, Nowell 
showed that the neoplastic progression occurs as a result of sequential selection of sub­
clones with increasingly dysregulated growth controls. This results in transformation of 
the nature of growth from a benign to a growth with malignant potential, which allows 
these strains to invade and undergo metastasis.
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1.11 Genetic instability of cancer
There are two opposing theories thought to be responsible for the genetic 
instability of cancer and they are somatic gene mutation and the aneuploidy hypothesis.
1.11.1 Somatic gene mutation hypothesis
Cancer inducing mutation could occur in normal spontaneous mutation in 
somatic cells, but numerous further alterations are needed for the progression of the 
cancer. The normal mutation rate is thought to be insufficient to accumulate the amount 
of genetic alteration required to result in a cancer. It is therefore, thought that the 
mutation occurs in a gene that is responsible for DNA fidelity. Dysfuntional oncogenes, 
tumour suppressor genes or DNA repair genes are thought to be important causes for 
this as it may result in the absence of important checkpoints that ensures DNA fidelity.
1.11.2 Aneuploidy Hypothesis
Chromosomal instabilities manifest as aneuploidy and the exact mechanism 
which triggers and drives this is unknown. There are different possibilities which could 
cause aneuploidy for Eg.sister chromatid cohesion, abnormal kinetochore structure or 
disruption of spindle check points.
Mitosis is a process which results in two identical daughter cells and this 
requires precision. The mechanism which ensures this has been a challenge for the 
scientists ever since this was shown by Theodor Boveri nearly 100 years ago. Any 
defects in the mitosis in the germ line results in embryonic lethality apart from certain 
chromosomal abnormalities which results in birth defects eg. Trisomy 21 results in 
Down’s syndrome. Most solid tumours demonstrate chromosomal instability and Boveri 
was the one who postulated that these changes could be the cause of tumour 
development.
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There are different types of genetic alterations in tumours:-
1. Subtle sequence changes: due to base substitution or deletion of few nucleotide 
and these changes are not detectable by cytogentic analysis e g., defects in 
mismatch repair is seen sporadic non familial CRC, defects in nucleoside 
excision repair is responsible for Xeroderma pigmentosa.
2. Aneuploidy: alterations in the chromosome numbers due to loss or gain of whole 
chromosome e g., loss of chromosome 10 results in glioblastoma, gain of 
chromosome 9 results in papillary renal cell carcinoma.
3. Chromosomal translocation: can be detected cytogenetically as fusions of 
different chromosome or of normally non contiguous segments of a single 
chromosome. For e g., Translocation of chromosome 9 and 22 is seen in CML.
4. Gene amplifications: seen cytogentically as homogenously stained regions .At 
molecular level, multiple copies of DNA megabases are seen and are different 
from the duplication of much larger chromosomes, which results in translocation 
or aneuploidy. Although it is well known that solid tumours have genetic 
instability, it is not their existence but the rate at which this occurs is of 
significant importance.
Aneuploidy is a state of abnormal chromosomal number and content. Some 
cancers may have stable chromosomal alteration as a result of chromosomal 
redistribution at some stage during the pathogenesis of the disease conferring it some 
proliferative advantage. But in majority of cell lines these indicate chromosomal 
instability and they are demonstrated well in the colorectal cancers (Lengauer et al
1997).
Aneuploidy can occur in several ways:
1. Aberrant mitotic division caused by polyploidisation, due to cytokinesis defects, 
cell-cell fusion or cell skipping mitosis together result in cells that enter the 
subsequent mitosis with multipolar spindle (Storchova et al 2004). It can also be
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caused by defects in duplication, maturation or segregation of chromosomes 
(Nigg 2001).
2. Chromosome cohesion defects might also result aneuploidy in human cancer 
cells. Separation of sister chromatids depends on separase and this is inhibited 
by securin. Human cancer cells in which securin is inhibited shows high levels 
of chromosomal instability (Jallepalli et al. 2001)
3. Aneuploidy can arise from improper attachment of microtubules from each pole 
to the one kinetochore (Cimini et al 2001) Inhibition of attachment -error -  
correction mechanism by aurora kinase B, borealin, survivin and inner 
centromere protein (INCENP)(Gassmann et al 2004).
4. Aneuploidy results from defects in mitotic check points that prevent cells from 
entering into anaphase if  all the chromosomes are not attached by microtubules. 
There are three checkpoints which are documented: DNA damage checkpoint, 
which is able to block cells in G l/ S, G 2 or even in mitosis (Hoeijmakers 2001), 
DNA replication check point that monitors progression through S phase, and the 
spindle check point, which monitors attachment of chromosomes to functional 
spindle microtubule and delays exit from mitosis until all chromosomes have 
bipolar attachment and thereby ensuring equal distribution of genomic material 
to the daughter cells. Spindle check point is discussed in detail in the further 
section in this chapter. Figure 1.6 illustrates the different components in mitotsis 
that may lead to chromosomal misaggregation and hence aneuploidy(Pihan, 
Doxsey 1999).
22
Figure 1.6 Mitotic Machinery and their functions
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Figure 1.6 Components of the mitotic machinery and their functions. Defects in several 
mitotic functions have the potential to contribute to chromosome missegregation, 
aneuploidy and tumorigenesis (Pihan, Doxsey 1999).
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1.12 Aneuploidy and cancer
Aneuploidy is commonly seen involving one or more chromosomes in human 
cancers (Sen et al 2001) and is the most prevalent genetic abnormality seen in solid 
tumours (Hein,Mittleman 1986).The association of cancer and aneuploidy is undisputed 
but the exact mechanism of the induction of aneuploidy and its role in the pathogenesis 
of cancer remains unknown.
It has been suggested that chromosomal instability (CIN: rate) results in 
aneuploidy (the state) is a dynamic chromosome mutation event and is a distinct form of 
genetic instability in cancer. This may lead to phenotypic alteration during the cell 
progression (Bialy et al 1998). Cancer cells may undergo structural and functional 
phenotypic changes. These include altered morphology, proliferative capacity and 
metastatic potential. They also develop traits needed to survive E.g., antigen resistance, 
immune resistance.
The identification of aneuploidy earlier in cancer development has suggested 
that this may play an important role in the development and progression of cancer 
(Barrett et al. 1999, De Angelis et al. 1999).Further support to the aneuploidy as cause 
for carcinogenesis is the fact that non -  genotoxigenic carcinogens such as asbestos and 
mitotic spindle blockers (e.g., colcemid) induces chromosomal instability leading to 
aneuploidy but they do not cause mutations.
The association of aneuploidy and gastrointestinal cancer is strong. It is common 
in colorectal, oesophageal and gastric adenocarcinoma. Tumours with aneuploidy tend 
to behave more aggressively (Doak 2008, Bondi 2009). In gastric cancer higher level of 
aneuploidy is associated with advanced tumours (Sugai et al 1999)and metastatic spread 
of gastric cancer (Sasaki et al 1999). Recurrent chromosomal abnormalities have been 
noted in gastric cancers but no particular aberration has been established as a specific 
cause for gastric cancer development. Chromosomes 1, 7, 8, 9, 17, 20, X an Y were the 
most commonly involved chromosomes. It has been observed that the genetic 
abnormalities seen in advanced gastric cancers are also seen in the early stages of
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gastric cancers implying that these changes are the most likely driving force in the 
development of the cancers (Hamamoto et al 1997). Beuzen et al showed that the same 
chromosomal abnormalities increased progressively with advancing pathological 
stages.In 2000, Kobayashi et al looked at the intestinal metaplasia and adenocarcinoma 
samples from the same patients and demonstrated that they share the same genetic 
abnormality but the abnormality was severe in cancer. They also showed that the loss of 
heterozygosity was more common in cancer when compared with intestinal metaplasia.
1.13 Methods of looking for aneuploidy
1.13.1 In situ hybridisation (ISH)
In situ hybridisation(ISH) involves binding of a labelled probe to the cellular 
DNA and is used to analyse the numerical and structural abnormalities in the 
chromosomes. This technique was developed in 1969 (John et el. 1969,Gall and Pardue 
1969). The probes used were radio isotope probes and were associated with long 
exposure times with radioactive materials and high background noise. This led to new 
techniques involving non isotope probes, which were considered safe and user friendly.
1.13.2 Fluorescence in situ hybridisation
Various methods using direct and indirect labelling were tried to overcome the 
disadvantages of isotope probes. Indirect labelling involved three basic steps -  a) 
preparation of the specimen in a slide b) introduction of a labelled probe which attaches 
to a specific homologous sequence on the DNA c) detection of this targeted area by 
another process. The labelled probe could be a fluorochrome linked to an antibody or a 
fluorescently labelled DNA. Flurochromes are chemical groups which emit a specific 
wavelength of fluorescent light after excitation light of a characteristic and longer 
wavelength. In this study, fluorescently labelled DNA probes were used. Fluorescence 
labelled signal is highly sensitive and allows detection of several different sequences 
using different coloured sequences simultaneously.
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Direct labelling with fluorescent probes established this technique as a widely 
used technique in cytogenetics. This involves directly labelling of the flourochrome to a 
DNA molecule and has advantage over the indirect labelling in that this method is both 
simple and quick to do. Another advantage of this method is that the probes can be 
removed relatively easily when compared to the indirect labelling and fresh probe can 
be used. The disadvantage with this is that the signal produced by the direct labelling 
cannot be amplified whereas the signal produced by the indirect method can be 
amplified.
1.13.3 Advantages of FISH
Conventional cytogenetic analysis involved using cultured cells to obtain 
metaphase preparations. FISH can be applied to inter phase cells and therefore enables 
us get the cytogenetic data from the inter phase cells, which was not possible in the past. 
The ability to get this data from the inter phase cells is likely to give us data that is more 
representative of the specimen as the data gathered from the cell culture could be 
influenced by the genetic composition of cells cultured through the selection of 
favourable growth characteristics.
Another advantage of these probes is that they are commercially available and 
several probes can be used in a single experiment, which conserves both labour and 
time. FISH is technically simple and speedy to analyse thereby enabling us to study 
loss/gain of chromosomes as well as deletions/amplification of chromosomes. 
Conventional molecular methods (like comparative genomic hybridisation) rely on bulk 
analysis and therefore has the potential to miss rare chromosomal abnormalities but 
FISH can easily distinguish and score many cells allowing detection of rare 
chromosomal abnormalities.
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1.13.4 Limitations of FISH
FISH is used to study either the whole genome or specific genomic loci. This 
depends on the probes used. This can be broadly divided into three subtypes, each with 
different range of applications (Kearney 2001) -  Whole chromosome painting probes; 
repetitive sequence probes and locus specific probes. Repetitive sequence probes 
hybridize specific chromosomal regions or structures that contain short sequences 
which are present in many thousand copies (Kemey 2001, Gozzetti 2000) Eg., 
centromeric probes that target the alpha and beta satellite sequences, which flank the 
centromeres of human chromosome. Centromeric probes are particularly suitable for the 
detection of monosomy, trisomy and other aneuploidies in solid tumors and leukemias 
(Gozzetti 2000). Numbers of signals from these probes are supposed to be identical to 
numbers of homologous chromosomes per interphase nucleus but however this is not 
the case (Lourov et al 2006, Louvrov et al 2007, Lourov et al 2009, Lierhr et al 2009). 
This is a main disadvantage of interphase FISH with centromeric probes. However this 
can be overcome with the use of site specific DNA probes (locus specific probes) 
(Lierhr et al 2009) Differences of hybridisation efficiency complicate simultaneous 
application of different set probes(Lourov et al 2006). DNA replication during the S 
phase of the cell cycle is another major problem of interphase FISH applications 
(Lourov et al 2006, Soloviev et al 1995) FISH analysis can be hindered by replicative 
signal appearance. This is mainly related to site specific probes but can also be seen in 
centromeric probes (Lourov et al 2006, Lourov et al 2007, Lourov et al 2009, Soloviev 
et al 1995, Yrov 2005).
The sensitivity and the resolution needed for the FISH experiment depends on 
the sensitivity and the resolution and that is directly attributed to the technical limits of 
the fluorescence microscopy. Sensitivity depends on the light gathering ability of the 
particular microscope. Resolution depends on the ability to distinguish between two 
points along the length of a chromosome. With technical difficulties in mind, we also 
need to consider the conformation of the DNA within the chromosome. Metaphase 
chromosomes are thousands of time more compacted that interphase chromosomes, 
which in turn are 10 times more compacted that the naked chromomses. This gives rise
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to resolution in the range of tens of thousands of kilobases for interphase chromosomes 
(O’ Connor 2008).
1.13.5 Brush cytology and FISH
Brush cytology using exfoliated gastric cells obtained during routine upper GI 
endoscopy was used in this study. This was chosen as it had been successfully used in 
the study of aneuploidy in Barrett’s oesophagus (Doak et al. 2003) and premalignant 
gastric tissue (Williams et al. 2005) by our group. The brushes were pushed through the 
endoscope channel and scraped along the gastric mucosa and collected the surface 
epithelial cells and did not penetrate into the stromal tissue (as in gastric biopsies).This 
method proved to be successful and subsequently used for this study.
1.13.6 Detection of abnormalities in chromosomel using FISH
Fringes et al showed that the human gastric cancer appear in two genomic 
groups that can be reliably diagnosed by FISH on routine biopsy specimens and that the 
numerical aberrations of chromosomes 1,3,10 and 17 are independent of histological 
subtypes and polysomic copy number abnormalities of chromosome 1 and 17 correlate 
to intra gastric tumour site and are highest in gastric cardia cancers, suggesting high 
tumour instability at this particular location. In 2000, Kitayama et al showed that the 
earliest chromosomal abnormalities that occur early in gastric carcinogenesis, involves 
aberrations of chromosome 1 and 2 and that chromosomal aberrations expand in a 
stepwise manner with cancer progression. In a recent study involving 51 gastric cancer 
patients, it was shown that aberrations of chromosomes 1, 8, 17, 20 and x were frequent 
regardless of the histological type of cancer (Kitayama et al. 2003). In this study, FISH 
was used to study the aberrations of chromosome 1 in the premalignant gastric tissues.
In this study, aberration of chromosome 1 was studied through the varying 
histological stages of gastric cancer development as outlined by Correa (Correa 1988). 
Premalignant lesions occur early during the neoplastic progression and they possess an 
increased risk for cancer development but only a certain proportion of the premalignant
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lesions are actually committed to neoplastic progression. Occasionally, premalignant 
lesions develop into tumours through a series of defined morphological events that can 
be staged by histology according to the disordered cell growth and loss of 
differentiation present. Such lesions have proven ideal human models for investigations 
into tumourogenesis, as the analysis of each stage allows the sequence of genetic events 
that eventually cause malignant transformation to be established. Understanding the 
genetic factors involved in the multistep progression of certain cancers could ultimately 
lead to streamlining the strategies involved in the surveillance, management and 
prevention of cancers. Genetic biomarkers may be identified that prove to have higher 
sensitivity and specificity, which will eventually lead to early detection of gastric 
cancers by stratifying the surveillance of these cancers and will also help in facilitating 
cancer prevention by early medical intervention. This could also lead to conserving the 
health resources and improving the cost effectiveness by relaxing or omitting the 
surveillance for patients with low risk of developing cancers.
1.14 The mitotic spindle checkpoint
The mitotic spindle checkpoint is a highly regulated feedback mechanism that 
plays an important role in the maintenance of genetic stability and integrity. This 
checkpoint ensures the correct attachment of chromosomes to the spindle microtubules 
during mitosis. Prevention of premature entry to anaphase is induced until all the 
chromosomes are correctly attached to the spindles. The spindle checkpoint therefore 
blocks chromosome segregation until the spindle has been correctly assembled and the 
bipolar attachment of the sister chromatid is achieved, ensuring that they are precisely 
divided into two daughter cells.
The spindle checkpoint acts as a surveillance system by monitoring the status of 
kinetochores -  a protein complex that is present on the centromeres of every 
chromosome during mitosis. The spindle microtubule attaches to the kinteochores in the 
chromosomes during mitosis. A single unattached kinetochore provides sufficient signal 
to activate the spindle check point, which triggers a signal cascade that induces the 
anaphase inhibitors (Nicklas et al. 1995, Chan et al 2005). Defects in spindle assembly,
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kinetochores, the structure/number of centromeres and the alignment/attachment of the 
chromosomes on the spindle triggers the mitotic spindle check point and delays the 
progression into anaphase until the defects are rectified. Alternatively, adaptation 
occurs, where a prolonged cell cycle arrest induces apoptosis or a return to the 
interphase occurs by overriding the spindle checkpoint mechanism (Gorbsky et al.
1998)
1.14.1 The mitotic checkpoint components and its mechanics
The components of the mitotic spindle cell checkpoints were originally 
identified in budding yeast by screening agents that induced de polymerisataion of the 
microtubule[(Hoyt et al 1991,Li and Murray 1991,Weiss and Winey 1996).
Mitotic progression and sister chromatid segregation is controlled by the 
anaphase promoting complex/ cyclosome. APC is a large protein complex that induces 
degradation of cohesion complex, which itself comprises of atleast four different 
subunits (allowing chromatid separation) and the mitotic cyclins responsible for 
maintaining mitosis. APC/C function is regulated by a) phosphorylation and b) 
association of activator protein Cdc20.Cdc20 has been implicated in the regulation of 
APC/C dependant proteolysis and is essential for chromosome segregation (Visintin et 
al. 1997). After ubiquitation APC/C initiates degradation of securin. Securase is 
inhibited by securin, a protein involved in the control of transition between the 
metaphase to anaphase, throughout the cell cycle. But when securin is degraded, 
separase is not inhibited and this leads to cleavage of protein subunit See 1.The cleavage 
of Sccl is irreversible, therefore very closely controlled. The cleavage of Sccl leads to 
dysjunction of sister chromatids and rapid transition from metaphase to anaphase. 
APC/C also leads to degradation of other protein called cyclin B1 and this leads to 
inactivation of CDK1 (cyclin dependant kinase 1) and initiates mitotic exit.
These events are controlled by the mitotic check point, and prevents premature 
advance into anaphase. The mitotic check point is activated immediately after the entry 
of cells into mitosis or meiosis. The signal for this is provided by unattached
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kinetochores. These trigger check point components which prevent the cdc20 dependant 
degradation of securin and cyclin B by activation of APC/C complex(Cleveland et al. 
2003).Experiments have shown that even one unattached kinetochore can delay 
anaphase. The other theory is that the lack of tension in the unattached kinetochores 
delays anaphase. Experiments in the insect spermatocytes suggested that it is the 
application of tension in the unattached kinetochore that allows anaphase onset (Nicklas 
et al 1995). It is a matter of controversy which exactly triggers the delay in the anaphase 
onset. In fact it has been difficult to distinguish between these as attachment of 
microtubule to kinetochore produces tension and this promotes attachment of additional 
tubules (King, Nicklas2000). Both unattached kinetochore and the lack of tension 
results in delayed anaphase signal through different check point components.
Initial studies involving the use of drugs to disrupt the mitotic spindle 
demonstrated two genetic factors in budding yeast that cause failure to arrest in mitosis 
and therefore were linked to a defective spindle check point. The mutants were named 
Mitotic Arrest Deficit (MAD 1, 2 and 3) and Budding uninhibited by Benzimidazole 
(BUB1, 2, and 3)(Hoyt et al. 1991, Li, Murray 1991). Homologues of BUB and Mad 
genes are identified in all higher eukaryotes suggesting the mechanism has been 
conserved throughout evolution. Only exception is that while yeast and plants have 
conserved Mad3 protein that lacks kinase domain, Drosophila and mammals have a 
protein that shares similarly to Mad3 at its N-terminus but also has a C terminal serine. 
The protein kinase domain, that is highly homologus to BUB1 and was therefore named 
BUBR1 and probably represents homolog of Mad3 (Chan et al 1999). The mitotic 
checkpoint requires BUBR1 kinase (a hybrid yeast MAD2 and BUB1, which is encoded 
by BUB IB gene), the ZWIO-ROD-Zwilch complex, CENPE (microtubule motor 
protein centromere protein E) and mitogen activated protein kinase (MAPK) to regulate 
the signalling pathway.
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The mitotic checkpoints are rapidly bound by and released by unattached 
kinetochores (Shah et al. 2004, Howell et al. 2004). After the nuclear envelope 
breakdown, the checkpoint proteins are recruited to the outer kinetochore surface of all 
the unattached kinetochores.
MAD1-MAD2, BUB1-BUB3 and BUB3-MAD2B/BUBR1 complexes along 
with the MPS1 protein are recruited to unattached kinetochores forming a large 
multiprotein complex. Fig 1.7 represents the role played by MPSl.The exact 
mechanism of this is unknown. It is indicated that BUB1 and BUB3 proteins are 
involved in recruiting the other checkpoint proteins to the kinetochore and this process 
activates and releases the MAD2 in a modified state. MAD2 forms a complex with 
CDC20-APC, inactivating it and halting the cell cycle progression.(Musacchio, 
Hardwick 2002, Millband et al.2002). MPS1 is known to phosphorlylate MAD1 during 
checkpoint activation (Hardwick et al. 1996)- this can re-release MAD2 but does not 
activate MAD2. MAD2 occurs in two forms-a dimer and a tetramer. Although the 
dimer and the tetramer binds the CDC20, the tetramer is believed to be active form 
involved in the inhibition of APC (Fang et al. 1998).
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Figure 1.7 Inhibitory effect o f  protein MPS in the event o f  unattached kinetochore
M P S l
f
Phosphorylation of MAD1
M P S l
$
Works upstream on other all 
other check points
Assosiation of MAD1 with 
MAD2
_____ f _____
Signal the presence of 
unattached kinetochores
Induce mitotic arrest on other 
spindle checkpoint components
Figurel.7. Represents the inhibitory effect o f  protein MPS in the event o f  unattached 
kinetochore that eventually leads to mitotic arrest.
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Direct binding of the protein CENPE (the microtubule motor protein centromere 
Protein E) to its binding partner BUBR1 activates the BUBR1 kinase activity(Mao et al.
2003).BUBR1 kinase activity is required for the recruitment of a stable MAD1-MAD2 
hetrodimer and this in combination forms the active MAD2(Chan et al. 1999, Mao et al. 
2003,Shah et al. 2004).Activated MAD2 and or BUBR1 in a complex with BUB3 is 
tightly associated with CDC20 and prevents it from activating the APC/C and thereby 
inhibiting the ubiquitination of securin, a protein involved in the control of metaphase -  
anaphase transition and cyclinBl (Fang et al. 1998)
The exact mechanism involved in the mitotic spindle checkpoint is not known, 
but the final pathway is the inactivation of the CDC20-APC complex (to prevent 
anaphase entry) in the presence of chromosomes unattached to the spindle. Dissociation 
of certain checkpoints from the kinetochore region and the CDC20-APC complex 
occurs after the bipolar attachment of the chromosomes and results in terminating the 
metaphase arrest (Figure 1.8).
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Figure 1.8 Events triggered by phosphoryation o f  protein CDC20
PHOSPHORYLATION/ASSOCIATION PHOSPHORYLATION/ASSOCIATION
OF ACTIVATOR PROTEINS LIKE c d c 2 0  OF ACTIVATOR PROTEINS LIKE c d c 2 0
*  9
APC/C ubiquitination APC/C ubiquitination
*  *
Degradation of securin Degradation of Cyclin B1
Activation of separase
clevage of cohesin 
subunit SCC1
Rapid transition of 
metaphase to anaphase
Figure 1.8 shows the cascade o f  events triggered by phosphoryation o f  protein CDC20 
which leads to the progression o f  cells from metaphase to anaphase.
9
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1.14.2 Mitotic checkpoint loss and aneuploidy
The components of mitotic spindle checkpoints were identified in studies that 
showed that the isolated mutated yeast strains were unable to activate mitotic arrest in 
response to the microtubule- damaging agents such as nocodazole and benomyl (Hoyt et 
al. 1991, Li, Murray 1991). This demonstrated that the disruption of the spindle 
checkpoint results in aneuploidy by enabling the premature exit from mitosis. This 
results in two daughter cells with unequal number of chromosomes.
As the defect in the spindle checkpoint plays an important role in the prevention 
of aneuploidy, there has been lot of interest in identifying the possible mitotic 
checkpoint defects in human malignancies that exhibit chromosomal instability.
MAD2 and BUB1 genes are frequently studied genes as they play an important role in 
the mitotic checkpoint. Mutations of the BUB1 gene have been identified in several 
cancers although at a low frequency. BUB1 mutations have been observed in 
lung(Gemma et al. 2001), thyroid(Ouyang et al. 2002) and colorectal cancers(Shichiri et 
al. 2002).Both increased and decreased levels of BUB1 expression levels have been 
observed in breast cancer cell lines (Myrie et al. 2000, Yuan et al. 2006) and colorectal 
cancers (Shichiri et al. 2002). A recent study has shown that BUB1 expression levels 
were significantly greater in the diffuse gastric cancer subtype when compared with 
intestinal type gastric cancer (Grabsch et al. 2004). It has also been shown that over 
expression of BUB1, BUBR1, BUB3 is associated with increased proliferation in 
gastric cancer (Grabsch et al. 2003). The regulation of gene expression of these mitotic 
checkpoints may therefore be an important factor that facilitates carcinogenesis.
Studies involving MAD2 genes are rare and the mutations of MAD2 are seldom 
found. MAD2 sequence variation has been found in breast cancer cell lines (Percy et al. 
2000). It has also been shown that reduced MAD2 gene expression levels have been 
associated with dysfunctional mitotic check point in breast, nasopharyngeal and ovarian 
cancer cell line ( Li,Benezra 1996, Wang et al. 2000,Wang et al. 2002). Over expression 
of MAD2 levels have also been observed in gastric cancers (Tanaka et al. 2001) but the 
levels of this over expression did not correlate with aneuploidy, clinical or pathological
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characteristics . Mutation has been observed in the MAD2 gene in gastric cancer 
suggesting these mutations could lead to the development and progression of gastric 
cancers. Wang et al (2009) have shown that the expression of MAD2 is related to the 
histological differentiation and lymph node metastasis of gastric cancer. The higher 
expression level of MAD2 was correlated with more poorly differentiated gastric cancer 
and lymph node metastasis. It was also shown that MAD2 is expressed mainly in the 
nucleus in gastric cancers whereas they are expressed mainly in the cytoplasm in gastric 
tissue. This shift was thought to be due to tumorogenesis. They suggested that MAD2 
might be a crucial marker of prognosis in gastric cancer and could be a target in the 
search for an effective treatment against gastric cancers.
These reports suggest that the steady -  state levels of MAD2 may be important 
in regulating the mitotic checkpoint. Therefore, inactivation of any of the components of 
the mitotic checkpoint may play an important role in the pathogenesis of cancer. The 
status of these genes and their expression levels in human cancers will help us 
understand the complex nature of the spindle check points and its role in carcinogenesis.
1.15 Gene expression
Only a small proportion of human genes are expressed at any given time and this 
depends on the cell type function and differentiation. Some genes are expressed in all 
the cells all the time and are called housekeeping genes and are essential for the very 
basic cellular function. Gene expression is regulated by alteration of the transcription 
and translation of the genes. All genes are surrounded by DNA sequences that control 
their expression and this done by producing proteins called transcription factors. These 
proteins can switch the gene on and off, thereby regulating it. These transcriptional 
factors are produced by a different gene, which is again regulated by a different set of 
transcriptional protein. There is a strict hierarchy in the regulation of gene expression. 
However, if a single gene is inappropriately expressed, serious dosage imbalances may 
be induced, particularly if the gene product is a key regulator of pathways vital for cell 
function or survival.
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Gene expression occurs in two major stages. The first stage is transcription, by 
which the gene is copied to produce a primary transcript (mRNA molecule) with 
essentially the same sequence as the gene. Most human genes are divided into exons 
and introns and only the exons carry information required for protein synthesis. The 
primary transcripts are processed by splicing the introns and leaving just the exons to 
form a mature transcript or messenger (mRNA) that contains only exon sequences. The 
second stage is protein synthesis and this is also called translation.
Abnormal expression of genes involved in cell growth, differentiation and 
division have a potential to result in cancer; up regulation of the proto-oncogenes c- 
erbB-2, c-myc and cyclin D1 have been associated with bladder, breast and gastric 
cancers respectively (Bieche et al 1999,Oda et al 1999,Underwood et al 1996). The 
steady-state mRNA levels within the cells under differing conditions can provide us 
with information of how a cell copes and adapts to a changing environment. The 
investigation of transcriptional levels in cells at differing stages of neoplastic pathway 
will provide us with valuable information regarding the gene expression patterns 
responsible for driving tumourogenesis. Such analysis relies on accurate quantification 
of mRNA concentration as a measure of gene expression and the most common method 
used is reverse transcription-polymerase chain reaction (RT-PCR)(Bustin 2000).
1.16. RT-PCR
RT-PCR is a sensitive technique used for the quantification of steady-state 
mRNA levels especially in samples with limiting RNA quantities. Reverse transcriptase 
is used to convert the mRNA to cDNA (complementary DNA) as the taq polymerase 
used in the PCR cannot use mRNA as a template. The reverse transcriptase enzymes 
catalyses the first strand of cDNA synthesis from mRNA in the presence of gene 
specific/non specific primers. Gene specific primers are used when analysing rare 
messages and it involves a single step so the chance of contamination is very low but 
the disadvantage with this primer is that separate RT reaction is needed for each gene 
studied. The use of non specific primers (e.g. oligo dT or random decamers) gives a 
cDNA pool which can be used for several subsequent reactions using a number of
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different gene specific primers. This is particularly advantageous if RNA sample is 
limited. PCR technique is used in amplifying the signal and is quantified
The PCR reaction involves an exponential phase (exact doubling of products 
occurs and is very specific), a linear phase (the reaction is slowing down and the 
products are starting to degrade) and endpoint phase (the reaction has stopped, no more 
products are formed and if left long enough degradation of the products occurs).
Therefore accurate detection and quantification of the resultant amplified 
product is paramount in studying the gene expression levels and the reliability of the 
data gathered using conventional RT PCR methods is poor(Bustin2002).
Conventional methods involved end-point analysis, which is a gel based method 
involving electrophoresis of the amplified products after completion of the PCR 
reaction. Subsequent quantification is achieved by using image analysis software. A lot 
of variables could affect the result -  small pipetting errors, errors in loading the gel and 
buffer could result in unreliable data and the image analysis method is subject to 
inaccuracies. It is also labour intensive.
Real time PCR uses the data gathered during the whole course of the PCR 
reaction and does not use any post PCR data. The quantification of a fluorescent 
reported that accumulates during the course of the PCR reaction is directly proportional 
to the amplicon generation. Therefore this eliminates the post -PCR processing for 
quantification of the amount of PCR produced. There are different types of fluorescent 
probes that could be used in the real time RT PCR reaction -  hybridisation probes, 
molecular beacons, and SYBR green. SYBR green probes were used in this study. This 
is an intercalating dye that binds to double stranded DNA via the minor grooves and as 
a result of this interaction, releases a fluorescent signal. The advantage of using this is 
that it binds to all double stranded DNA eliminating the need to optimise specific 
probes. As the product of the PCR reaction accumulates with each cycle, the fluorescent 
signal emitted from the chosen probe/dye increases in direct proportion. Real time PCR 
has greatly improved the reliability, reproducibility and the accuracy of the RT -PCR. 
Real time RT -PCR is used in various fields -  it is used in viral detection, detection of
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gene expression levels, genotyping, drug therapy efficacy, DNA damage measurement 
and pathogen detection. Real time PCR is also considered to be more sensitive than 
endpoint analysis and as a result is increasingly used for mRNA quantification (Mok et 
al 2001, Sgroi et al 1999).
1.16.1 The analysis of real time PCR
The basis of the real time PCR is that as the double stranded DNA accumulates 
during the PCR reaction, the fluorescent signal released increases in direct proportion 
and therefore this can be detected and quantified. The software on automated thermal 
cyclers (e.g. BIO RAD icycler) commercially available performs the data analysis. The 
increase in the fluorescence is plotted against the cycle number to determine the 
threshold cycle (Ct) of the sample -  the point at which the fluorescent signal can be 
detected above the background fluorescence. This is then plotted against the 
automatically calculated standard curve (from a reference series of samples) and from 
this the initial template quantity within the sample is calculated. The sensitivity of 
fluorescence detection and the high sensitivity of PCR in amplification of a single 
template allow detection of mRNA from even single, laser micro-dissected cells (Bustin 
et al 2002).
1.17 Aims and Hypothesis
1.17.1 Hypothesis
1. Recent studies have shown that aneuploidy in chromosome 1 and 4 are common 
in gastric cancer (Kitiyama 2000, Fringes 2000) and aneuploidy in chromosome 
occurs early in gastric cancer (Kitiyama 2003). It is hypothesised that if the 
aberrations in chromosome 1 and 4 are common and seen in early gastric cancer, 
then it is likely that they are common and are significant in the premalignant 
stages of gastric cancers
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2. Family history, smoking habits and H .pylori infection play an important role in 
gastric cancer pathogenesis and this could be due to facilitation of chromosomal 
instability in the premalignant stages of the gastric cancer.
3. MAD2 and BUB1 are widely studied genes that control spindle cell check 
points and alteration of gene expression levels may lead to increased aneuploidy 
levels of chromosome 1 and 4.
4. Family history of gastric cancers, smoking, and H, pylori play an important role 
in gastric cancer pathogenesis and they may contribute to the alteration of the 
gene expression levels of MAD2 and BUB1.
1.17.2 Aims
1. To study chromosomal aberrations in chromosomes 1 and 4 in all premalignant 
stages of gastric cancer.
2. To correlate the known risk factors of gastric cancer like family of gastric 
cancer, smoking and Hpylori infection with the aneuploidy levels of 
chromosome 1 and 4.
3. To study the gene expression levels of MAD2 and BUB1 in the premalignant 
stages of gastric cancer.
4. To correlate the MAD2 and BUB1 gene expression levels with the aneuploidy 
levels of chromosome 1 and 4.
5. To correlate the MAD2 and BUB1 gene expression levels with the known risk 
factors of gastric cancers like family history of gastric cancers, smoking and H. 
pylori infection.
1.18 Summary of experimental approach
Patients were recruited from an open access endosopy list after obtaining their 
consent, a brief questionnaire were filled in to assess their risk factors for the 
development of gastric cancer. At endoscopy, gastric cells were obtained using gastric 
cytology brush.These cells were used to analyse the aneuploidy levels of chromosome 1 
and 4. Gastric biopsies were obtained during the procedure and depending on the patient
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tolerance, upto three samples were taken. These samples were used for H. pylori 
detection, histological staging, and obtaining RNA, which was used in the gene 
expression levels of MAD2 and BUB1 levels.
The following chapter deals with the materials and methods used in this study. 
Chapter 3 details the results of the levels of aneuploidy using flourescent insitu 
hybridisation technique. Chapter 4 investigated the levels of MAD2 and BUB1 levels 
using RT-PCR technique on the RNA extracted from the gastric biopsy specimen 
obtained at different stages of premalignant gastric cancer stages.
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CHAPTER 2
Materials and methods
This chapter outlines the process involved in patient recruitment and data 
collection in those patients enrolled in the study in chapter 3 and in chapter 4. The 
method of cell collection from the endoscopic samples is described and also the 
Fluorescent in situ hybridisation used to detect the chromosomal aberrations. This 
chapter also explains the method adopted to get the tissue samples, the method used to 
extract the RNA from the gastric biopsies, , the statistical methods used to analyse the 
results of the interphase FISH, the gene expression levels of MAD2 and BUB1 levels, 
as well as the process whereby the histological diagnosis of gastric biopsies was made.
2.1 Patient enrolment into the study
The study enrolled samples from the Neath Port Talbot Hospital and the Royal 
Glamorgan Hospital, South Wales. The Neath Port Talbot hospital is situated in the 
mixed rural and urban area of West Wales and serves a population of approximately 
140,000. The Royal Glamorgan Hospital serves the area of Rhonda Valley. These two 
areas represent similar population demographics and characteristics in that they both are 
ex mining areas and are. Prior to the start of the study Ethical Approval was obtained 
from Dyfed ethics committee, October 2007. The study was performed between 
October 2007 and January 2010.
Initially the patients were enrolled from the Royal Glamorgan Hospital as a 
similar study was being conducted in that hospital. I not only learnt the method used to 
enrol patients for the study, the use of gastric cytology brush to obtain the gastric cells, 
transferring the cells to a transport media and the method used in the lab to obtain the 
cells on to the slide. This helped me immensely in enrolling the patients independently 
at the Neath Port Talbot Hospital.
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Patients enrolled in this study were identified during routine endoscopy waiting 
lists at Neath Port Talbot Hospital and also from the Royal Glamorgan Hospital, 
Llantrisant. Only the patients attending my lists at Neath Port Talbot Hospital and the 
patients attending the lists of the gastroenterologists at the Royal Glamorgan Hospital 
were invited to participate in the study. Patients who were enrolled in this study were 
above 18 years of age, were not on any anti coagulants or medications prolonging their 
clotting time, and were enrolled from an open access list from their primary physician. 
An informed consent was obtained from these patients prior to the upper GI endoscopy. 
The samples were collected and transferred to the university to analyse the samples, 
whenever possible on the same day. Two or three samples were collected during an 
endoscopy list due to the time constraints on a busy endoscopy schedule.
Exclusion to the study were made when it was felt that the patients could not 
adequately consent (<18 years, unable to give informed consent).Patients who were 
taking drugs, which could prolong the bleeding For Example., warfarin were not 
included in this study. In an effort to achieve informed consent an information leaflet ( 
Appendix -1 ) were sent out to all patients together with their appointment letter and a 
discussion of the leaflet was made prior to the consent (Appendix -2 ). A short clinical 
questionnaire was given to the patient to fill in before their endoscopy and information 
regarding age, sex, diet, smoking, alcohol consumption and drug intake were gathered 
(Appendix -3). This information was the only source of information and I did not 
corroborate this information by reviewing their medical records.
2.2 Endoscopic cytology brushings
During the upper GI endoscopic examination, endoscopic cytology brushes 
(gastric cytology brushes, Premier endoscopy) were used to exfoliate the cells from the 
gastric and oesophageal mucosa of various histological stages. The endoscopic 
procedure was prolonged by 2-3 minutes to collect the brushings and the biopsies 
needed for the study. Figure 2.1 shows an upper GI endoscope. Gastric brushings were 
performed first and then the biopsies were taken from the same site Figure 2.2 shows a 
cytology brush and Figure 2.3 shows a cytology brush coming out of a biopsy channel
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from the upper GI endoscope. The brushings were performed first as taking the biopsies 
initially would have contaminated the cytology with red blood cells. If the area was 
normal the brush/biopsy were taken from the gastric antrum but otherwise they were 
taken from the abnormal area. This methodology has been described and successfully 
used by Doak S et el in our laboratory Patients with bleeding tendencies, patients on 
anticoagulants and those with obvious bleeding lesions at the time of procedure were 
not included in the study. No patients reported any immediate complications following 
their endoscopic procedure. The patients were observed between two to four hours after 
their procedure before their discharge and were advised to seek medical attention if they 
noticed any bleeding.
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Figure 2.1 Upper GI Endoscope
Figure 2.1 shows an upper gastrointestinal endoscope.
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Figure 2.2 Cytology brush
Figure 2.3 Cytology brush through an endoscope
Figure 2.3 shows a close up view o f  a cytology brush coming out of  a biopsy channel 
and the figure below shows how the cytology brush is used by an endoscopist to obtain 
gastric cells during an endoscopy.
The yield o f  gastric cells was poor during the initial stage o f  the study. This was 
thought secondary to the difficulty in maintaining good contact between the cytology 
brush and the gastric mucosa due to the angle between the gastric wall and the 
endoscope. The yield was also poor if any food residue, bile or blood were present in 
the stomach. The bile, food and blood were sucked through the endoscope, the area was 
flushed with 20 -  30 ml o f  sterile water and the excess water was sucked prior to the use 
o f  gastric cytology brush.
The cytology brushes were immediately placed into universal tubes containing 
10 ml o f  ETN buffer (0.1M EDTA, 0 .01M Tris-Hcl, 0.02M Sodium Chloride, pH 7) as 
described for oesophageal brushes (Doak et el 2003), on ice, in the endoscopy 
department for transportation to the University for laboratory analysis. Vigorous 
shaking o f  brushes immediately after the brush was placed in the ETN buffer was found 
to improve the cell yield. The cells were usually harvested within 24 to 48 hours.
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Occasionally, the cells were stored up to 4 days. At first, the brushes were transported 
from the Endoscopy unit in 10ml of 90% methanol, on ice, but in spite of harvesting 
these cells within 4 hours, the cell yield was unreliable and the medium was changed to 
ETN buffer.
2.3 Cell Cleansing
Gastric cells were difficult to harvest and were partially digested with no clear 
cell membrane or cytoplasm. The oesophageal cell yield was adequate most of the time. 
This improved with the change in the media to ETN buffer.
The cell suspension was centrifuged at 1500 rpm for 10 minutes and the 
resultant cell pellets were re suspended in ETN buffer. This washing step was repeated 
twice in order to remove cell debris and bacteria that would affect the scoring of the 
signals. If the cell pellet produced was small, the third wash was omitted but otherwise 
this was performed. The resultant cell pellet was re suspended with 0.5 ml of ETN 
buffer and a cytodot was produced on a glass slide using Cytospin (Thermo Shandon 
Cytospin 4). Larger pellets were re suspended in 1ml of ETN buffer.
2.4 Slide Generation from Cytology Brushings
Glass slides (pre- cleaned with 100% ethanol to remove the dirt) were assembled 
in a cytospin clamp with a filtercard and funnel according to the manufacturer’s 
instructions and placed into a cytospin (Thermo Shandon Cytospin 4). One Hundred 
microlitres of the resultant cell preparation was added to the cytofunnel in the cytospin 
and spun for 5 minutes at 1200rpm to produce a cytodot. The cytodot was examined by 
a light microscope, and the respective cell suspensions was diluted or concentrated 
accordingly to ensure that an adequate number of single layered cells were present on 
the slides for the interphase FISH. The resultant slides were fixed in 90% methanol for 
10 minutes, left to dry and then stored at -20C. An average of 2-5 slides was produced 
per sample.
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2.5 Flourescence Insitu Hybridisation
2.5.1 Reagents
1. 20x SSC
3M NaCl plus 0.3 Tris -  Sodium Citrate.
87.5grams NaCl/ Tris -  Sodium Citrate in 50 ml of deionised water
2. 2xSSC
50 ml of 20x SSC in 450 ml of deionised water adjusted to pH7
3. 2x SSC/ 0.1% NP-40:
500pl of NP- 40 in 500 ml of 2x SSC adjusted to pH 7
4. 4xSSC/0.3% NP-40.
1.5ml of NP-40 plus 100 ml 2xSSC in 400 ml of deionised water adjusted to
pH -7 .5 .
All the above reagents were stored under ambient conditions for up to 6 months.
5. 70%, 80% and 95% ethanol made up with deionised water.
6. lx P B S : 0.1M Na2HP04 plus 0.1 M NaH2P04 plus 0.1% w/v NP- 40
17.9gNa2HP04 plus 7.8gNaH2P04 plus 500pl NP 40 in 500 ml of deionised
water
This reagent was stored at 4D C and discarded after 6 months.
2.5.2 Pre treatment of interphase cell preparation
Treatment with pepsin was performed to remove the cytoplasmic protein probe 
improving the penetration of the probes into the cells. Interphase cell preparations and 
300pl/ ml of 0.01 M of pepsin (pH 2.7-3) were incubated at 37 □ C for 10 minutes and 
then treated with pepsin at the same temperature. Several drops of pepsin were applied 
to the cytodot and they were left at 37 □ C. The cytodot treatment with pepsin was left 
for 5 minutes but this was reduced to 2 minutes as it was thought that treatment for 5 
minutes could be responsible for over digestion of gastric cells resulting in the loss of 
nuclei. This suggested that partial gastric cell digestion occurs after the collection phase 
of the endoscopy and treatment with pepsin for more than 5 minutes could have
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accelerated this process resulting in poor interphase FISH. The slides were washed in 
PBS for 5minutes and followed by a further 5 minutes in PBS/MgC12 at room 
temperature. This is to arrest the enzymatic action of pepsin. The slides were then 
dehydrated with increasing concentration (70%, 80%, and 95% for 2 minutes each) of 
ethanol to prepare them for the denaturation step prior to FISH.
2.5.3 FISH probes
Commercially available centromeric enumeration probes (CEN) for 
chromosomes 1 and 4 (Abbott/Vysis Cat no Cepl orange: 06J36-001 CEP4 green: 
06J37-004) were used. The probe vials were briefly centrifuged for a few seconds 
before opening them in order to collect the probe at the bottom of their containers, thus 
minimising any loss of the probes.
2.5.4 Probe Mixture
A probe master mixture was made in a 0.5ml microfuge tube with the following 
components for each slide:
3.5pl of hybridisation buffer (supplied by the manufacturer with the probe)
0.5 pi of each probe for hybridisation
Purified water to bring the volume of probe plus water to 1.5pL (For example if using 
one probe: 0.5pL of probe plus lpl of water and doubling these when using for two 
probes)
This mixture was pipette repeatedly to mix the contents thoroughly.
These two probes were used simultaneously and the FISH was performed
according to a slightly modified manufactures instructions. In 51 samples both the
probes were used at first but the signal from the probe used for chromosome 4 were
nonspecific, therefore only chromosome 1 was studied during the latter part of the study
involving 10 samples. 5pi of probe mixture was added to each cytodot (3.5pi
hybridisation buffer, 0.5pl of each probe and 0.5pl of water). The sample and probe
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were co-denatured on a 75degreesC hotplate for 2 minutes (the edge of the cover slip 
was sealed using a rubber cement) and was incubated in a humidified chamber which 
has been preheated to 37C for 30 minutes. The cover slip was removed and the slides 
were washed in 0.4 SSC solutions for 2 minutes for 2 minutes, followed by washing it 
again with 2 X SSC solutions at room temperature for 30 seconds. This was left to air 
dry in the dark. To the nuclei was countersigned by adding lOpl of DAP I (Vectorshield 
with DAPI Cat no. H-1200 ) to the slide.
2,6 Signal visualisation and scoring
An (Zeiss Imager Z1 Axio) microscope and (Bio Rad) software was used to 
score each slide. An average of 182 cells was studied per sample. Nuclei that were 
smeared or overlapping were excluded.
CEN probes highlight the centromere of the chromosome and were used to 
determine the entire chromosomal changes i.e., aneuploidy. A loss of a CEN signal said 
to be due to deletion of that chromosome and more than 2 signals denotes amplification. 
Slides were coded prior to scoring, with no knowledge of the histological details of the 
tissue samples. Figure 2.4 shows an example of a normal cell and an aneuploid cell.
2,1 Statistical analysis of chromosomal abnormalities
Paired two tailed student’s t test was used to compare the chromosomal changes 
between the various histological diagnoses. Statistical significance was achieved if the p 
value was less than 0.05.Correlation coefficient was calculated between the age and 
aneuploidy levels. If the correlation coefficient was between -0.09 to 0.09, there was no 
correlation between these two variable, if  the correlation coefficient is between -0.3 to
0.3, then the correlation between them is small, between -0.5to -0.3 or 0.5 to 0.3, then 
the correlation between these two variables are medium and the correlation is 
considered to be strong if the levels are between -.0.5to-1.0 or 0.5 to 1.0. Standard error 
of mean is used as it is an estimate of the amount that an obtained mean may be 
expected to differ by chance from the true mean. The smaller the standard error, the
52
more representative the sample is to the overall population. The standard error also 
depends on the sample size. It is inversely proportional to the sample size. For e.g. the 
larger the sample size, the smaller the standard error because the statistic will approach 
the actual value.
2.8 Histological Diagnosis of tissue biopsies
The histological diagnosis of the endoscopic biopsies taken at the Neath Port 
Talbot Hospital were determined by Dr AP Griffiths, Consultant Histopatholgist based 
at the ABM University Hospital and also the histologists based at the Royal Glamorgan 
Hospital.
2.9 Gastric Biopsies at endoscopy
During the upper GI endoscopic examination, gastric biopsies were obtained 
from the same area after the cytology brushing was done. Two biopsies were taken from 
the same area of brushings and a third biopsy was obtained if the patient tolerated the 
procedure. A typical endoscopy takes approximately 5 minutes and taking the samples 
prolonged the procedure by an extra 2-3 minutes as they have to go into the relevant 
transporting medium and labelled before proceeding to the next sample. It was not 
always possible to get the third sample for various reasons. Of the three biopsy samples, 
the first was stored in RNA later, the second one was sent to histological analysis and 
the third one was used to perform CLO test (Bripharm Ltd., UK).
2.10 H.pylori testing method
Gastric biopsies were obtained during the endoscopy; one of the biopsies was 
used for the detection of H. pylori infection. CLO test was used for this in the 
endoscopy unit. The biopsy was placed on a special slide containing urea and an 
indicator such as phenol red. The urease produced by H. pylori hydrolyzes urea to 
ammonia, which raises the pH of the medium and this leads to a change in colour 
(yellow to start with, changed to red/dark pink if it is positive). This may sometime take 
up to 24 hours and the results are read the day after the endoscopy. There are rapid CLO
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test available which can be read within 30 minutes of performing the test and is this is 
useful in letting the patients of their condition and the need to treat it on the day of the 
procedure.
2.11 Precautionary measures to prevent RNA contamination
To prevent cross contamination between samples and prevent carryover of 
nucleic acids from one experiment to another the following precautions were taken:
1. The workstations were wiped with commercially available RNase free solutions.
2. The samples were prepared in a laminar flow hood equipped with a UV lamp 
and pre cleaned with RNase free wipes (Ambion UK, Cambridgeshire).
3. This area was different from the thermal cycler area to avoid cross 
contamination with plasmids or amplicons.
4. Gloves were changed frequently between each stage of procedure.
5. Only RNase free filter pipette tips were used.
6. A no- template control was used to all PCR assays to verify that no 
contamination has occurred during the procedure.
2.11.1 RNAse free wipes
Ribonucleases (RNAse) is a type of nuclease that degrades RNA into smaller
components. They play an important role in the nucleic acid metabolism. They are
found in both prokaryotypes and eukaryotyes and are present in almost every cell type.
The human body secretes RNAse in tears, saliva, mucus and perspiration and this is
used in the defence against invading microorganisms. The primary source of RNAse is
microorganisms like bacteria, fungus, and their spores. RNAse contamination can easily
occur in the lab as bacteria, fungi and their derivates (Eg. restriction enzymes,
polymerases) are widely used in the experiments. The prevention, detection and
elimination of nuclease contamination are a constant challenge to anyone working with
RNA in the lab. All intracellular RNAs are protected by various strategies including
5’end capping, 3’end polyadenylation, and folding within an RNA protein complex
(ribonucleoprotein particle or RNP). RNAses like RNAseA and T1 are secreted in large
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amounts by non specific cells. These can render any RNA that is not in a protected 
environment to degrade rapidly.
For this entire study, various precautionary measures were taken to ensure that 
the experiments were performed in an RNAse free environment. This has been listed 
earlier in this section. Laboratory surfaces such as bench tops, centrifuges and pipettes 
should be assumed to be contaminated with RNAases and necessary precautions taken 
to get rid of them before starting the experiments. Elimination of RNAses from these 
surfaces is easy and can be done by using RNAse decontamination solution such as 
Ambion’s RNaseZAP. RNaseZap is a combination of three different chemicals that will 
completely inactivate RNAses immediately on contact. This solution is sprayed directly 
to the surface and wiped clean with nuclease free water. RNAse wipes are towelettes 
that are pre-soaked with RNAase decontamination solution (Ambion RNaseZap wipes 
was used in this study).These are particularly convenient for decontaminating pipettes, 
work tops and other surfaces.
2.12 Extraction of RNA
The gastric tissue sample was cut into small pieces and transferred into a 2.0mL
safe- lock micro centrifuge tube containing 500 pL TRIZOL reagents. The sample was
then homogenised using a rotor- stator homogeniser for 30 seconds and was incubated
at room temperature for 5 minutes. The homogenised mixture was immediately frozen
in -80 □ c or immediately proceeded to phase separation. Almost all the samples
underwent immediate phase separation. One hundred micro litres of chloroform was
added to this and the resultant mixture was vortexed for 20 seconds, followed by
incubation for 5 minutes at room temperature. The resultant mixture was then
centrifuged at 12,000 revolutions per minute in a pre -  cooled centrifuge at 4 DC.
Following centrifugation, the mixture separates into a lower red, phenol -  chloroform
phase, an opaque interphase, and an upper colourless aqueous phase. The RNA remains
exclusively in the aqueous phase. Precaution was taken not to disturb the resultant
centrifuged mixture and the red chloroform phase and the opaque interphase were
discarded. The aqueous phase was pipette using a RNA free filter pipette tips and
transferred to a 2.0 mL safe -  lock micro centrifuge tube and 70 % ethanol was added
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to bring the total volume to 350 pi. The resultant mixture is mixed thoroughly by using 
a pipette with a RNA free filter tip.
Seven hundred microlitres of the sample was transferred to an RNeasy column 
placed in a 2 ml collection tube and the flow through is discarded. Three hundred and 
fifty pL of buffer RW1 was added to the RNeasy spin column and this was centrifuged 
at 10,000 rpm to wash the spin column membrane. The flow through was discarded. 
Ten pL of the DNase stock solution was added to the 70pL of the buffer RDD. This was 
mixed by gently inverting the tube and centrifuging briefly to collect any residual liquid 
from the sides of the tube (RDD buffer is supplied with the RNAse -  Free DNase set). 
The DNase incubation mix (80pL) was added directly to the RNeasy spin column 
membrane, and placed on the bench top at 20-30 DC for 15 minutes. Three hundred and 
fifty pL of RW1 buffer was added to the RNeasy spin column and this was centrifuged 
at 10,000 rpm and the flow through was discarded.
Add 500 pL of the buffer RPE (buffer supplied by the supplier) to the RNeasy 
spin column. The lid was closed gently and centrifuged at 15rpm to wash the spin 
column at 8000rpm. The flow through was then discarded. The collection tube was used 
later. After centrifugation, the RNeasy spin column was carefully removed from the 
collection tube so that the column did not contact the flow -  through. The RNeasy spin 
column was placed in a 1.5pL collection tube and 30 -50pL of RNase free water was 
added directly to the spin column membrane. This was centrifuged at 8000 rpm for a 
minute to elute the RNA. If the expected RNA yield was less than 
30 pgm, this step was repeated to obtain more RNA from the sample. Each resultant 
sample RNA was divided into lOpl aliquots, stored at -70 □ C and discarded after 
freeze/thawing twice.
56
2.13 Reverse transcription of RNA
A 10 jj.1 aliquot of RNA obtained and stored at -  80 □ c and a reference RNA , 
also stored in -  80 □ c were thawed per PCR plate at 4 □ C..The gDNA wipe out 
buffer, Quantiscript reverse transcriptase, Quantiscript RT wipe out buffer, RT primer 
mix (Qiagen quantiscript reverse transcription kit) and RNAse free water were also 
thawed in a lamina flow hood that has been thoroughly pre cleaned with RNase wipes 
(Ambion UK, Cambridgeshire) at the room temperature for approximately 15 minutes.
The gDNA reaction was performed in a 0.2ml microfuge tubes... The RNA 
sample were normalised to lpg RNA in 12pL RNAse free water. Two micro litres of g 
DNA wipe out buffer was added to the 12 pi of RNA sample to make up a total volume 
of 14pL.The resultant mixture of RNA and gDNA wipe out buffer was vortexed briefly 
for few seconds to allow thorough mixing of the RNA sample and gDNA wipe out 
buffer, followed by centrifugation and incubation for 2 minutes at 42 □ C using a 
g DNA protocol on BIO-RAD i cycler. Figure 2.4 shows the gDNA reaction 
conditions.
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Figure 2.4 A normal and aneuploid cell.
Normal Cell with diploid nuclei. The two red dots represent chromosome 1 and the two 
green dots represent chromosome 4.
Aneuploid y o f  chromosome 1
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The RT master mix was prepared by mixing:
1 pL of Quantiscipt reverse transcriptase,
4pL of Quantiscript RT buffer 
lpL of RT primer mix
This was prepared by initially adding 1 pi of RT primer mix followed by 4 pi of 
quantiscript RT buffer and adding the 1 pi of reverse transcriptase just before the RNA 
sample is taken out from the BIORAD /cycler machine. This was vortexed briefly to 
allow efficient mixing of all the constituents and the resultant solution was centrifuged 
briefly. The total amount of reverse transcriptase master mix solution required, during 
that particular experiment was calculated by multiplying the amount required for each 
sample i.e., 6 micro litres by the number of samples. Six micro litres of this RT master 
mix was added to each g DNA elimination reaction (14pL), resulting in a total volume 
of 20 micro litre of total volume. This was vortexed briefly to allow them to thoroughly 
mix and was centrifuged following this
This was then taken back to the BIORAD /cycler (Figure 2.6 show the Bio Ra 
RT PCR machine) and the reverse transcription reaction was performed by using RT 
protocol setting on BIO-RAD / cycler. This was a predetermined setting and was not 
changed thorough the study. The only variable which could be changed was the volume 
used during a particular experiment, which was again set at 20 pi thorough out the 
study. The RT protocol involved incubating the samples for 15minutes at 42 □ C, 
followed by 3 minutes at 95 □ C. Figure 2.5 shows the conditions used in the reverse 
transcriptase procedure.The reverse transcription negative controls were not 
performed.The primers used were intron spanning and were optimised in previous 
experiments performed in our lab, thereby minimising the carry over of any gDNA. 
Also, gDNA digestion buffer was used in the RNA extraction process and also gDNA 
wipeout buffer was used during the reverse transcriptase reaction.
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Figure 2.5 Reverse Transcriptase Procedures
Incubate a t 42 deg rees Celsius for 2 min
Incubate a t 42deg rees Celsius for 15 min
'
Mix RNA,gDNA wipeout buffer, and  
R N ase-free w ater
rr ^ 
Add Q uantiscript R everse  transcrip tase  
RT buffer, and  RT prim er mix and  mix
\
f  V
Incubate a t 95degree  celsius for 3min 
to inactivate reverse  transcrip tase
\
r
Add cDNA to real tim e PCR mix and 
distribute
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Figure 2.6 Bio Rad RT PCR machine
Figure 2.6 shows the Bio Rad RT PCR machine.
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Serial dilution of reference cDNA was made in order to get a 1:10, 1:100 and 
1:1000 dilution of the reference RNA. This was achieved by pipetting 18pL of RNAse 
free water was in three 0.2mL tubes and they were labelled as 1:10, 1:100 and 1:1000. 
Two pL of neat reference RNA was added to the first tube labelled as 1: 10 and this was 
mixed by vortexing briefly and centrifuging for 1- 2 minutes approximately. Two micro 
litres of this solution (1 in 10 dilutions) was added to the tube marked 1:100 (this has 18 
p 1 of RNase free water) and this was vortexed and centrifuged. Two micro litres of 1 
in 10 dilution solution was added to 18 pi of RNase free water, giving a dilution of 1 in 
100. The resultant solution of a 1 in 100 dilution was briefly vortexed and centrifuged 
for 1 -  2 minutes. Two micro litres of 1 in 100 dilution solution was added to the tube 
marked 1:1000 (this has 18 pi of RNase free water) and the resultant solution was 
vortexed briefly and centrifuged for 1 -  2 minutes giving a 1 in 1000 dilution.
2.13 Primers
Primers are designed to amplify a fragment of cDNA 100-150bp in size from the 
MAD2, BUB1 and p Actin genes. The primers are intron spanning and were designed 
and optimised in our lab for an earlier study(Doak et al 2003) In order to allow analysis 
of all the targets simultaneously using the same thermal cycling conditions, the primers 
were designed to anneal at the same the same temperature, the resultant primer 
sequences are detailed in the following Table 2.1
Table 2.1 Real time RT-PCR primer sequences
Gene for 
amplification
Forward Primer Sequence Reverse Primer Sequence
MAD2 GGTCCTGGAAAGATGGCAG ATCACTGAACGGATTTCATCC
BUB1 AGGATCTGCCCGCTTCCC GTCGTCTGATAGGTTACTGG
B Actin GATGGCCACGGCTGCTTC TGCCTCAGGGCAGCGGAA
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2.14 Reference gene
The house keeping or reference genes are routinely used in qPCR to normalise 
experimental data, such as differences in RNA quantity and quality, the overall 
transcriptional activity and differences in cDNA synthesis (Thellin et al 1999) 
Theoretically, all reference genes are supposed to exhibit consistent, non -  regulated, 
stable expression among different tissues (Radonic et al 2004, Vandesompele et al 
2002) However, cancer development is a very complex stepwise process involving 
altered cell functions at many steps, through changing almost all genes in gene 
expression(Brumy et al 2005, Lyng et al 2008). Many experimental evidences indicate 
that even the so called housekeeping genes (HKSs) are involved in tumorigenesis, 
including breast,prostate,colorectal, and bladder-cancer(Lyng et al 2008, Hsiao et al 
2001, Butte et al 2001, De Kok 2005, Shmmittgen et al 2000, Goiding et al, Ohl et al 
2005, Khimani et al 2005). Typical housekeeping genes including gyceraldehydes 3- 
phosphonate dehydrogenase(GAPDH), beta-actin(ACTB), TATA- binding 
protein(TBP),18S ribosomal RNA(18S) and many more have been adopted from the 
literature without taking into account their specific tissue dependent behaviour or the 
special design of the respective study (Vandesompele et al 2002, De Kok et al 2005, 
Khimani et al 2005) The possibility of deregulation of the so called housekeeping genes 
for qPCR normalisation in cancer research may lead to unreliable results and 
misinterpretation of the results (Schnmittgen et al 2000, Ohl et al 2005, Dheda et al 
2005). A comprehensive literature review of expression studies in high impact journals 
showed GADPH, ACTB, 18S RNA and 28sRNA were used as a single control gene in 
more than 90 % of cases (Vandesompele et al 2002).
Reference genes have been described for RT-PCR in various studies in various 
cancers of other tissues (Jung et al 2007, Huang et al 2003, Gao et al 2008). However, 
there seems to be no consensus on reference genes for gene studies in stomach cancer 
(Hyun et al 2010). Hyun et al found out 115 articles published between May 2007 to 
November 2009 -  GADPH (46%) and ACTB (35.7%) were the most frequently used 
reference genes in gastric cancer studies. They also showed that ACTB and GAPDH
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showed most abundant expression in both’ stomach cancer cell lines’ and ‘non stomach 
cancer cell line’. Hyun et al also studied the stability of various reference genes and the 
best single reference gene for each group as follows ; ‘non- stomach cancer cell line’- 
GAPDH, ‘stomach cancer cell lines’ -  RPL29(ribosomal protein29),’tumour stomach 
tissue’ -RPL29,and ‘all stomach cell lines and tissues’- ACTB. Beta actin (ACTB) was 
used in this study as it is one of the most commonly used housekeeping genes in the 
gastric cancer study. The choice of reference gene should depend on the cell lines 
or/tissue under study and there is no single, universal optimal reference gene.
2.15 Limitations of SYBR green
Real time PCR can be performed by using probe based systems -
1. Taqman probes (Heid et al 1996)
2. Molecular beacons (Piatek et al 1998)
3. Fret probes (Chen et al 1999)
4. Scorpions (Solinas et al2001)
5. iFret probes (Howell et al 2002).
An alternative to the probe based system is the use of fluorescent double 
stranded DNA (dsDNA) -  specific intercalating dyes and the example of this are YO- 
PRO -l(Ishiguro et al 1995) SYBR green 1 (Wittwer et al 1997, Ririe et al 1997), BEBO 
(Bengstsson et al 2003), and LC Green (Witter et al 2003) and they have been tesed in 
real time PCR applications.
SYBR green 1 is used commonly as it is cost effective compared to the probe 
based system and it also allow for generic detection of amplified DNA, and can be used 
to differentiate DNA by DNA melting curve analysis (Wittwer et al 1997, Ririe et al 
1997).However, the limitations of SYBR is that it needs to be optimised and certain 
agents needs to be added to improve reaction efficiency, such as bovine serum albumin 
and Triton- X I00 (Bengstsson et al 2003). The SYBR green used in this study was an 
optimised Super mix produced by BIO RAD systems, which contained 2 reaction
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buffers, iTaq DNA polymerase, Magnesium hydrochloride, SYBR green 1, fluorescein, 
and stabilisers.
Another limitation of the SYBR green is that depending on the reaction 
conditions, the dye also appears to have an inhibitory effect on the PCR in a 
concentration dependent manner (Wittwer et al 1997, Witter et al 2003). This has been 
shown to be overcome by increasing the concentration of magnesium chloride in the 
reaction ( Bengstsson et al 2003, Witter et al 2003). The degradation products of the dye 
have been shown to be inhibitory to the PCR reaction (Witter et al 2003). A further 
limitation of SYBR green 1 is that it appears to have limited application for the analysis 
of multiplex PCR and has selective detection of amplicon during DNA melting curve 
analysis of multiplex PCT. In a study by Giglio (2003) et al multiplex PCRs for Vibrio 
Cholerae and Legionella pneumophilia analysed by DNA melting curve analysis using 
SYBR green found only one amplicon could be detected by melting curve analysis but 
both amplicons were amplified as determined by agarose gel electrophoresis.
2.16 Real time RT PCR
All reactions were set up in a laminar flow fume hood using sterile nuclease free 
pipette filter tips. The fume hood and all equipment to go into it were cleaned with 
RNase free wipes prior to use and no tip boxes were opened outside the hood.
The components of each reaction included:
12.5 pi of IQ SYBR Green Super mix (BioRad, Hertfordshire, UK) 
pi of Forward Primer 
pi of Reverse Primer
BIO-RAD z'Q SYBR Green super mix, primers (lOpM forward and reverse) and 
RNAase free water were thawed at room temperature.
A PCR master mix were prepared for each gene i.e., MAD2, BUB1 and P actin in 
1.5ml tubes for all reactions. Twelve and half micro litres of SYBR green, 5pL of
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forward and reverse primers, 6pL of nuclease-free water were mixed for each reaction.
A total amount of 450pL of SYBR green, 180pL of primers, 216pL of nuclease-free 
water was prepared for each 96 well 0.2 ml PCR plate (BioRad, Hertfordshire), which 
was used for the three genes used in this study (MAD2, BUB1 and (3 actin). The PCR 
master mix was vortexed briefly and centrifuged for 2 -  3 minutes to ensure that the 
exact component quantities were present in well in the PCR plate.
Seventy five micro litres of this PCR master mix is aliquoted into 0.2mL tubes, 
and 5 pi of the sample DNA was added to this. Five micro litres of the diluted reference 
c DNA was added to each aliquot of the 75 pi of PCR master mix and 5 pi of RNase 
free water was added to the no template control tube (this was included to as negative 
controls). All of these were vortexed briefly and centrifuged for 2-3 minutes. Twenty 
five microlitre of PCR master mix/cDNA (sample DNA, reference DNA in serial 
dilution and no template control) was pipetted to a 96 well plate in triplicates, ensuring 
exact quantities were present in each triplicate. Figure 2.7 illustrates a 96 well plate. 
Once all 25 pi reactions were loaded into the wells, the plate was sealed with Optical 
Sealing Tape (BioRad, Hertfordshire, UK). This was centrifuged briefly to collect all 
the contents in the bottom of the wells. The sample plate was then slotted into an 
/Cycler iQ Thermal cycler (BioRad, Hertfordshire, UK) and real time PCR was 
performed using a PCR program ‘Sher 60 ’. The cycling conditions for QPCR are 
illustrated in table 2.2. The programme was performed with the setting of persistent well 
factors, which was used throughout the run. The data obtained was stored in the 
computer attached to BioRad /cycler.
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Table 2.2 Cycling conditions of qPCR
Cycle 1 Cycle2 Cycle3 Cycle 4 Cycle5
Step 1 Stepl Step2 Step3 Stepl Stepl Stepl
Repeats 1 40 1 1 40
Dwell
time
(Mins)
3.00 0:30 0:30 0:30 0:30 0:30 0:30
Set point 95.0 94.0 60.0 72.0 55.0 95.0 55.0
PCR Melt
curve
End temperature of 94°C.
Table 2.2 shows the cycling conditions used in the Sher 60 protocols. There are three 
major steps in PCR, which are repeated for 30-40 cycles. During Cycle 1 denaturation 
takes place at 95°C, the double stranded DNA melts open to single stranded DNA, all 
enzymatic reactions stop. During the cycle 2, annealing occurs when ionic bonds are 
constantly formed and broken between the single stranded primer and single stranded 
template. The more stable bonds lasts a bit longer and on that little piece of double 
stranded DNA (template and primer); the polymerase can attach and start copying the 
template. Once there are few bases built in, the ionic bond is so strong between the 
template and the primer, that it does not break anymore. At 72°C, extension occurs and 
this is the ideal temperature for the polymerase. As both strands are copied during this, 
there is an exponential increase in the number of copies of the gene.
67
Figure 2.7 96 Well plate
Figure 2.7 showing a 96 well plate that was used for the RT-PCR.
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2.17 Data analysis
All data analysis was performed on the iCycler iQ5 software version 2.1 and 
each sample was individually analysed.
The melting curves generated for all the samples were first analysed to 
determine the specificity of the PCR products that has been generated. Samples without 
any correct melting curve were removed from the subsequent analysis. An example of 
meltcurve is shown in figure 2.8. Samples that did not have correct melting 
temperatures were excluded from the study.
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Figure 2.8 Primer test -  Melt curve
Melt Peak Chart Primer T est 2009-06-06  Q uantifast Sher60 .opd
T em perature, Celsius
Fig 2.8 shows example of  a melt curve for a MAD2, BUB1 and ACTB PCR products.
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The soft ware calculated the Ct value ( the threshold value -  this is calculated by 
detecting the fluorescent signals over the baseline cycle range and then setting it fixed to 
fixed threshold level at a statistically significant point above the baseline). Once set, the 
resultant Ct is recorded for each member of each triplicate is examined for any 
individual outliers and if there are any outliers, these were removed and regarded as an 
invalid data as it could have been due to experimental error for example pipetting etc., 
and as this could potentially skew the results. Figure 2.9 shows an amplification plot for 
a sample with its Ct (threshold cycle).
The software used then generated a standard curve from the p actin dilution 
samples and this was used to assess the quality of experiments involving the extracted 
DNA. The efficiency of each PCR reaction was determined by an equation
E= [10(' 1/a)] -1, where a=slope of the standard curve.
An optimum efficiency of 1.0 is obtained when the standard curve slope is -3.3.
Figure 2.10 shows the examples of typical real time PCR standard curves.
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Figure 2.9 Amplification plot for a sample with its Cy (threshold cycle)
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Fig 2.9 shows an amplification plot for a sample in triplicate illustrating its C j  
(threshold cycle) and the plots baseline.
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Figure 2.10 shows the examples o f  typical real time PCR standard curves.
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2.18 Statistical analysis of the gene expression levels
Paired two tailed student’s t test was used to compare the MAD2, BUB1 
expression levels between differing histological diagnoses. Statistical significance was 
achieved if the calculated p values were less than 0.5, documented as p<0.05.Again, 
Correlation coefficient was calculated between the age of the patients and the MAD2 
and BUB1 expression levels and the strength of correlation coefficient is calculated as 
explained above.
2.19 Justification of the statistical methods
T-test was used as it is a simple, straightforward, easy to use and adaptable to a 
broad range of situations, T-test is most commonly used method to evaluate the 
differences in means between two groups. T -test can be used even in the sample sizes 
that are very small. Paired two tailed T-test was used to look for variation of statistical 
significance in both directions of normal distribution in the given sample. Correlation 
coefficient was used to look for any correlation between two variables like age and 
aneuploidy as it measures the strength of linear relationship between the two variables.
2.20 Histological analysis of the gastric samples
All the samples used for the real time PCR were obtained at the Neath Port 
Talbot hospital. The histological staging was performed by Dr. AP Griffiths at the ABM 
University Hospital.
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Chapter 3
The analysis of chromosome abnormalities in gastric premalignant
tissue using Interphase Fluorescence In situ Hybridisation (FISH)
3.1 Introduction
Correa’s pathway suggests that there is a multistep precancerous process that 
leads eventually to the development of gastric cancers. Gastric carcinoma is a result of 
various genomic changes that affects the cellular function and results in cancer 
development. The studies looking at the cytogenetic abnormalities in gastric cancer are 
summarised in table 3.1.
Table 3.1 The results of a number of cytogenetic studies looking at chromosomal 
aberrations in gastric cancer.
Author Sample
size
Cancer type Chromosome
Panani
1995(Greece)
11 10/11 intestinal 
(3 metastatic)
3,- gain and loss 
6- gain and loss 
Translocation between 
chromosome 3 and 5 
Trisomy of 8 in one patient.
Kokkola 1998 
(Finland)
22 Intestinal Gain-20q, 17q,loss-18q,4q
Koo 2000 
(South Korea)
37 50% intestinal 
(22/37 metastatic)
Gain-8q, 7pq,13q,7 q 
Gain-18q,20pq,loss-17p
Fringes 2000 
(Germany)
20 Intestinal/diffuse Gain-1(63%), 17
Beuzen 2000 
(France)
60 Cardia, antrum and 
oesophageal
7,8,11,17,18,Y 
(40-65% all cancers)
Han 1996 
(South Korea)
18 Diffuse Widespread numerical 
rearrangements
Chun 2000 
(South Korea)
6 Advanced Loss-17p (100%) 
Gain-7
Igashari 2000 
(Japan)
39 Gastric carcinoma lp lost in advanced gastric 
carcinoma
Kitiyama 2000 
(Japan)
24 Various stages of 
gastric carcinoma
1,2- early 
1,2,4,20- later
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Sud 2001 
(UK)
26 17 intestinal 
9 diffuse
Loss-22q, 14q,4q, 17q
Wu 2001 
(Taiwan)
53 65% advanced 
55% intestinal 
45% diffuse
Gains- 8q, 6q, l lq ,  13q, 7p, 17p,
20p
Loss- 16q,19p,5q,3p,4q,lp
Sugai 1999 
(Japan)
99 65 intestinal 
34 diffuse
Aneuploidy in 73%
Kitayama 2003 
(Japan)
51 Aberrations of chromosome 
1,8,17,20 and X
Rodriguez 1990 9 Gastric and
oesophageal
adenocarcinoma
l ip  13-15 in 8
Falchetti (2008) 159 All types of 
Gastric cancer
Microsatellite instability
Ottini(2006) Review All types of 
Gastric cancer
Microsatellite instability
Hamamoto(l 997) 15 Gastric cancers 
with precancerous 
lesions
Frequent alteration at the locus 
DlS191(lq)
In this series of in vivo experiments patients with premalignant gastric disease 
were enrolled in the endoscopy, brush cytology, biopsies were taken to determine the 
histological stage and for H. pylori detection. Brush cytology using exfoliated gastric 
cells obtained during the endoscopy were used to look for aneuploidy in chromosome 1. 
Fluorescent insitu hybridisation technique was used to determine the chromosomal 
abnormalities. Although, the aim of this study was to look for the aneuploidy levels of 
chromosome 1 and chromosome 4, only the data from chromosome 1 was used as the 
signals received from Chromosome 4 were non specific.
3.1.1 Factors affecting the specificity of DNA probe hybridisation
There are various factors which could affect the specificity of a probe. If the 
exact nucleotide sequence of the DNA in the cell is known, a precise complementary 
probe can be designed. If even 5% of the base pairs are not complimentary, the probe 
will only hybridize loosely to the target sequence. In addition to this, the melting 
behavior of the probe depends on the temperature, the composition of the hybridization
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buffer and on the probe length. Any variation in the above mentioned factors may lead 
to the probes being washed away during the wash steps, probes may not be detected, or 
only some of them may be detected or may be non-specific and will not be accurately 
representative. FISH experiments used the same hybridization conditions for both 
Chromosome 1 and 4. The signals from chromosome 1 were specific and were used in 
the study, where as the signals from chromosome 4 were non-specific and could not be 
used. This is most probably due to the nucleotide sequencing in the DNA probe used.
3.2 Results
3.2.1 Patients enrolled in the study
There were 72 patients enrolled at the Endoscopy department of the Neath Port 
Talbot and Royal Glamorgan hospitals. Samples from 61 patients were suitable to 
perform FISH. Initially, samples did not yield good amount of cells for the study but 
this improved as the study progressed as improvements were achieved in collecting, 
transporting and fixing the samples. Patient details were collected from the patients 
prior to the endoscopy and the information collected was not confirmed by checking 
their medical notes as this would have resulted in prolonging the procedure time and 
increased the waiting time for other patients in the list. This may have resulted in 
underreporting of the risk factors associated with the development of gastric cancers.
Table 3.2 shows the age, sex, family history, smoking and dietary habits, alcohol intake 
and histological diagnosis of these patients.
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Table 3.2 Patient characteristics
Patient
No. Histology Sex
Age at 
Endoscopy PPI NSAID Smoking Diet Clo Alcohol
1 Normal m 52 No No DK Normal
Not
done
within 
recommend 
ed limit
2 Gastritis m 55 No No DK Normal
Not
done
within 
recommend 
ed limit
3 Atrophy m 34 No No DK Normal
Not
done
within 
recommend 
ed limit
4 Gastritis f 29 Yes No DK Normal
Not
done
within 
recommend 
ed limit
5 Normal f 49 No No DK Normal
Not
done
within 
recommend 
ed limit
6 Gastritis m 88 Yes Yes DK Normal
Not
done
within 
recommend 
ed limit
7 Normal m 57 No No DK Normal
Not
done
within 
recommend 
ed limit
8 Gastritis f 64 No No DK Normal
Not
done
within 
recommend 
ed limit
9 Gastritis m 70 Yes Yes DK Normal
Not
done
within 
recommend 
ed limit
10 Gastritis m 62 Yes Yes DD Normal
Not
done
within 
recommend 
ed limit
11 Normal f 51 Yes Yes DK Normal
Not
done
within 
recommend 
ed limit
12 IM m 51 Yes No DK Normal
Not
done
within 
recommend 
ed limit
13 Atrophy m 69 Yes Yes DK Normal Pos
within 
recommend 
ed limit
14 Gastritis f 57 No No DK Normal
Not
done
within 
recommend 
ed limit
15 Gastritis m 83 Yes No DK Normal
Not
done
within 
recommend 
ed limit
16 Normal f 23 Dk No DK Normal
Not
done
within 
recommend 
ed limit
17 Gastritis f 82 No Yes DK Normal Pos
More than 
recommend 
ed limit
18 Gastritis m 67 No Yes DK Normal
Not
done
within 
recommend 
ed limit
19 Gastritis f 74 No No DK Normal
Not
done
within 
recommend 
ed limit
20 Normal f 58 No Yes DK Normal Not within
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done recommend 
ed limit
21 Gastritis f 49 No No DK Normal Pos
within 
recommend 
ed limit
22 Gastritis m 50 DK No DK Normal
Not
done
within 
recommend 
ed limit
23 Gastritis m 75 DK No DK Normal Pos
within 
recommend 
ed limit
24 Gastritis f 47 DK No DK Normal
Not
done
within 
recommend 
ed limit
25 Gastritis m 43 DK No DK Normal
Not
done
within 
recommend 
ed limit
26 Gastritis f 60 DK No DK Normal
Not
done
within 
recommend 
ed limit
27 Gastritis f 38 No No Dk Normal
Not
done
within 
recommend 
ed limit
28 Normal m 57 DK No Dk Normal Yes
within 
recommend 
ed limit
29 Gastritis f 41 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
30 Gastritis f 78 Yes No
No
smoking Normal
Not
done
within 
recommend 
ed limit
31 Gastritis m 64 Yes No
No
smoking Normal
Not
done
within 
recommend 
ed limit
32 Normal f 70 No Yes
No
smoking Normal
Not
done
within 
recommend 
ed limit
33 Barretts m 60 No No Ex smoker Normal
Not
done
within 
recommend 
ed limit
34 Barretts m 85 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
35 Normal m 56 No No Smoker Normal
Not
done
within 
recommend 
ed limit
36 Barretts m 56 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
37 Gastritis f 60 No Yes Smoker Normal
Not
done
within 
recommend 
ed limit
38 Gastritis f 55 No No
No
smoking Normal
not
done
within 
recommend 
ed limit
39 Barretts m 68 No No
No
smoking Normal
not
done
within 
recommend 
ed limit
40
Normal
Oes f 69 No No
No
smoking Normal Pos
within 
recommend 
ed limit
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41
Oesophagi
tis m 45 Yes No Smoker
Less 
than 5 
portions 
of
fruits/ve
getable
Not
done
within 
recommend 
ed limit
42 Gastritis m 50 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
43 Gastritis m 61 No No
No
smoking Normal Neg
More than 
recommend 
ed limit
44 Gastritis f 68 No No
No
smoking Normal Pos
within 
recommend 
ed limit
45 normal m 55 No No Ex smoker Normal Neg
within 
recommend 
ed limit
46 Normal m 49 No No Smoker Normal Neg
within 
recommend 
ed limit
Al
Oesophag
us m 55 No No Ex smoker Normal Neg
within 
recommend 
ed limit
48 Gastritis f 81 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
49 IM m 70 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
Oesophag
us f 81 No No
No
smoking Normal
Not
done
within 
recommend 
ed limit
Gastritis f 63 Yes No
No
smoking Normal Neg
within 
recommend 
ed limit
Gastritis m 36 Yes No Smoker Normal Nd
within 
recommend 
ed limit
53 Gastritis f 79 Yes No
No
smoking Normal Yes
within 
recommend 
ed limit
54 Gastritis f 54 No No
No
smoking Normal
Not
done
Normal
Limits
55 Gastritis m 73 DK DK
No
smoking Normal
Not
done
Normal
Limit
56 Gastritis m 54 DK DK
No
smoking Normal
Not
done
Excess
Alcohol
57 Gastritis m 49 DK DK
No
smoking Normal
Not
done
Within
normal
limits
58 Gastritis f 54 DK DK
No
smoking Normal
Not
done
Within
normal
limits
59
Intestinal
metaplasia m 60 DK DK
No
smoking Normal
Not
done
Within
normal
limits
60
Intestinal
metaplasia f 69 DK DK
No
smoking Normal
Not
done
Normal
limits
61 Gastritis m 78 DK DK
No
smoking Normal
Not
done
Normal
limits
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Smoking was considered significant if they smoked more than 5 cigarettes per 
day and the alcohol history was considered significant if the alcohol consumption was 
above the national recommended limits (21 units a week for men and 14 units per week 
for women) .Family history of all upper GI cancers were noted. A total number of 61 
patients were enrolled in the study. Fifty percent of the patients were male.
3.2.2 Histological diagnosis in the study
Figure 3.1 shows the histological distribution of the samples collected. The histology 
was broadly divided into normal, gastritis, Intestinal metaplasia or atrophy. The gastritis 
was not further subdivided into active, chronic or reflux gastritis due to the number 
involved. Again, we have not differentiated between the atrophy of gastric glands and 
the intestinal metaplasia due to the numbers involved. These two histologies represent 
the later stages of neoplastic development in the Correa’s pathway (Correa 1988) and 
they all represent various precancerous stages in the development of gastric cancers. It 
should be remembered that the progress through the stage could be arrested at any point 
in the pathway and in instances regression of the staging could take place.
81
Figure 3.1 Illustrating the histology of  samples collected.
■  n o r m a l  o e s o p h a g u s  (n=4)
■  B a r r e t t ' s  o e s o p h a g u s  
(n=4)
■  n o r m a l  s t o m a c h ( n = 1 4 )
■  H.Pylor i  a s s o c i a t e d  
g a s t r i t i s ( n =1 0 )
■  H.Pylor i  n e g a t i v e  
g a s t r i t i s ( n =2 4 )
■  I n t e s t i na l  m e t a p l a s i a ( n = 5 )
Fig 3.1 Histology of  the samples collected during the study. Predominant abnormal 
histology is H .pylori negative gastritis (n=24), followed by H .pylori associated 
gastritis (n=10) and then intestinal metaplasia (n=5).
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As explained in the previous chapter, cytology brushes/biopsies were collected 
from the gastric antrum. Of the sixty one patient samples collected, fourteen patients 
had normal gastric mucosa, ten patients had gastritis which was associated with H. 
pylori and twenty four had gastritis but were H. pylori negative. Five patients had 
intestinal metaplasia or atrophy. Eight patients of sixty one had their oesophageal brush 
analysed in this study. Four of them had Barrett’s oesophagus and the other four were 
normal. These samples acted as an internal control for this study.
3.2.3 Risk factors associated with gastric cancer
Risk factors commonly associated with gastric cancers are male sex, increasing 
age, family history and poor socioeconomic conditions. Smoking, high alcohol intake 
and poor dietary habits have also been implicated in the development of gastric cancers 
(Wu et al. 2001). It has been noted that the risk of gastric cancer in smokers is dose 
dependant and the risk is even higher if this is combined with high alcohol intake 
(Sjodahl et al. 2007).It has been noted that patients who have first degree relatives with 
gastric cancer are likely to have increased incidence of gastric cancer when compared to 
the general population and this seems to vary with the ethnic group (Yaghoobi et al. 
2009).
3.2.4 Aneuploidy levels in males and females
There was no significant difference in aneuploidy levels between male and 
female patients (aneuploidy levels in male 4.56% and females 3.55%, p value 0.45). We 
had approximately equal number of patients and it is interesting to observe that there 
was no difference in aneuploidy levels between the genders although gastric cancers are 
considered to be predominantly a disease of men.
Figure 3.2 shows the difference in the aneuploidy levels between males and females.
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Figure 3.2 The difference in the aneuploidy levels between males and females, patients 
below 60 years and above 60years.
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Figure 3.2 Twenty three male patients had 4.56% of aneuploidy cells and the rest o f  the 
females had 3.55% of aneuploidy cells. 24 Patients were less than 60 years old with 
3.74%of aneuploid cells and the percentage o f  aneuploidy cells were 4.7% in patients 
above 60 years.
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3.2 .5  A n eu p lo id y  levels accord in g  to the age
Correlation coefficient was calculated between the aneuploidy level of 
chromosome 1 and the age o f  the patients. The correlation coefficient was 0.12, 
indicating a weak positive correlation.
Figure 3.3 shows the correlation between the age of  the patients studied and the 
level o f  aneuploidy found in them.
Figure 3.3 The aneuploidy level according to the age.
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Figure 3.3 shows the correlation between the age o f  the patients and the aneuploidy 
level of chromosome 1 (correlation coefficient -0.12).
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3 .2 .6  A n eu p lo id y  levels in high risk  o ld er  m en and low  risk yo u n g er  fem ales
Therefore it was interesting to see if there was any difference in the aneuploidy 
levels between young female patients (age less than 60 years), whose relative risk of 
developing cancer is low with older men (age above 60 years), who are considered at 
higher risk to develop gastric cancer. However, this also failed to show significant 
differences (aneuploidy in males over 60years is 4.80% and females under 60 years is 
3.15%, p value 0.07)
Figure 3.4 shows the aneuploidy levels between the males above 60 years and females 
below 60 years and vice versa.
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Figure 3.4 There is no significant difference between the aneuploidy levels between the 
high risk elderly males and low risk females in this study. 10 male patients above 60 
years had aneuploidy levels o f  4.80% and 10 female patients below 60 years had 
aneuploidy levels o f  3.15% (p value -  0.07).
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3.2.7 Aneuploidy levels in H. pylori infection
Helicobacter pylori infection has been strongly implicated in the development of 
gastric cancer. The determination of H. pylori in the gastric mucosa of the samples 
collected was performed using a standard haematoxylin and eosin staining of the gastric 
mucosa and also included searching for the organism with an oil immersion lens when 
gastritis was present by a consultant histopathologist with an interest in 
gastroenterology. An additional biopsy was also taken when possible to look for H. 
pylori infection using a CLO test and this involves change in colour of a special 
medium by an enzyme called urease produced by H. pylori in the gastric mucosa. The 
change in colour could take up to 24 hours and the test is usually considered negative 
after observing the media for at least twenty four hours to forty eight hours. This is 
usually performed by specialist nurses who work at the endoscopy department of the 
hospital.
A clinical questionnaire was obtained from the patients prior to their upper GI 
endoscopy to ascertain their drug history and they were specifically asked regarding the 
use of proton pump inhibitors and also use of non steroidal anti-inflammatory drugs. 
The use of proton pump inhibitors could mask the infection of H. pylori as it can make 
them migrate to the upper part of the stomach and this could lead to false negative 
results in the CLO test as the biopsies were commonly taken from the gastric antrum in 
patients with normal gastric mucosa. The aneuploidy for chromosome 1 was 3.78 in 
patients with gastritis and 5.055 in patients with H. pylori associated gastritis and this 
was significant (p =0.03).
Figure 3.5 shows the difference in aneuploidy levels depending on the H. pylori 
infection status.
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Figure 3.5 shows the aneuploidy levels depending on the H.pylori status
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Fig 3.5 the aneuploidy levels (5.74%) in 8 patients with H. pylori associated 
gastritis was significantly higher (p=0.03) compared to the aneuploidy levels (3.78%) in 
the 24 H. pylori negative patients.
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3.2.8 Aneuploidy levels in patients taking NSAID’s and PPI
Information regarding the use of non steroidal anti inflammatory medication was 
obtained as there are studies which have shown that their use could lead to lower 
incidence of gastric cancer (Lindblad et al 2005). Hence, it would be interesting to 
observe if their use led to any difference in the aneuploidy levels. These questionnaires 
were filled in by the patients and sometime by the nursing staff due to the constraints of 
the time placed by a busy endoscopy list. We had to rely on patient’s memory and 
corroborative evidence for this was not sought by looking through their clinical notes or 
ringing their primary physician responsible for their care.
There was no significant difference in the aneuploidy levels between patients 
who were taking a proton pump inhibitor and there was no significant difference in the 
aneuploidy levels depending on the use of non steroidal anti inflammatory medications. 
Figure 3.6 shows the difference in the aneuploidy level with the PPI use. There was no 
difference in the aneuploidy levels between taking a proton pump inhibitor or not if the 
histology was not taken into effect. Even if the histology of the patient was taken into 
effect, there is no difference in the aneuploidy levels in the histological subgroups of 
normal or gastritis patients.
The data for non steroidal anti inflammatory drug consumption was available 
only for 16 patients. The aneuploidy levels are higher in patients who took the non 
steroidal anti-inflammatory medications when compared with the patients who did not 
take them (aneuploidy level of 4.13 in patients who took NSAIDS and aneuploidy level 
of 3.42 in patients who did not take the NSAIDS, p value 0.376). This is contrary to the 
belief that the anti inflammatory medications may play a protective role in the 
pathogenesis of gastric cancers. But the numbers here are relatively small and it was not 
possible to analyse the effect of the anti inflammatory medications in comparison with 
the histological stages. Figure 3.9 shows the difference in the aneuploidy levels with 
NSAID use.
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Figure 3.6 shows the aneuploidy levels and the use o f  proton pump inhibitor
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Fig 3.6 Fourteen patients were on a proton pump inhibitor and the aneuploidy levels in 
those patients were 4.80% whereas 8 patients were definitely not on a PPI and the 
anuploidy levels in them were 3.65%. There was no significant difference in the 
aneuploidy levels between them (p-0.37)
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Figure 3.7 shows aneuploidy levels with NSAIDS use
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Fig 3.7 Ten patients were on a non steroidal anti inflammatory medication (NSAID) and 
the aneuploidy levels in them were 4.13 and there were eight patients who were not on a 
NSAID and the aneuploidy levels in them were 3.42. There was no significant 
difference in their aneuploidy levels between them p-0.20).
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3.2.9 Chromosomal abnormalities in gastric tissue at different stages of
disease severity
Cells from gastric tissue with different histological stages were examined for 
abnormalities for chromosome 1 using interphase FISH. Centromere probes were used 
for this purpose. Cells were also obtained from the oesophagus of some patients as an 
internal control. Loss or gain of chromosome 1 was noted and figure 3.9 shows the 
breakdown of the losses or gains of chromosome 1 in this study. The percentage of 
aneuploidy was higher in abnormal gastric tissue i.e., gastritis and intestinal metaplasia 
when compared with normal gastric tissue. This was observed in spite of the fact the 
normal gastric tissue was found to be more unstable than the oesophageal tissue. There 
was an obvious trend for the instability to increase with histological progression, from 
normal gastric through to gastritis and then to intestinal metaplasia and atrophy. In the 
gastritis group, it was observed, in patients with H. pylori ,the instability was higher 
when compared with patients who were found to be not infected with H. pylori using 
the above mentioned methods to detect it.(aneuploidy levels in H. pylori negative 
samples is 3.74 and in H. pylori positive samples is 5.055, p value 0.03)
A total of over eleven thousand cells were studied using CEN probe 1 looking at 
the abnormalities in chromosome 1. Seventy percent of the abnormality was loss of a 
chromosome and 15 percent of the abnormality was gain of chromosome 1. The rest of 
the abnormality was gain of more than one chromosome. Three or four chromosome 1 
were found in certain samples.
Figure 3.8 shows the common abnormalities in chromosome 1 found during the FISH 
analysis. Figure 3.9 represents the variation in the level of aneuploidy across the patient 
group involved and shows that there are group of patients with high aneuploidy 
levels(highest 12% ) and also patients with low aneuploidy levels(lowest 0.4%). Figure 
3.10 demonstrates the variation in the aneuploidy levels in comparison with the 
histological progression. Error bars denote the standard deviation, showing the variation 
in the data.
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Figure 3.8 shows the abnormalities in chromosome 1 found during the FISH analysis
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Fig 3.8 The predominant abnormality seen in the chromosome 1 was loss o f  one 
chromosome 1, which accounted for more than 70% o f  the abnormality, followed by 
gain of chromosome 1 in 15 % of the abnormality. Various other abnormalities 
including 3 or more chromosome 1 were seen in the rest 15%.
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Figure 3.9 shows the variation in the aneuploidy levels in the patients enrolled in this 
study
>-g
_ o
ada
c
<
-C
a>u
O)
CL
13.00
12.00
11.00
10.00
11 1fi ?1 ? R 31 3fi 41 4fi R1
N u m b e r  o f  P a t i e n t s
Fig 3.9 represents the variation in the degree o f  aneuploidy o f  chromosomel seen in 
the sample studied. This varied from aneuploidy of 0.4% to very high aneuploidy o f  
more than 10% of the cells studied in some patients.
94
Figure 3.10 shows the aneuploidy levels and the various stages of  histology
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Figure 3.10 the percentage o f  aneuploidy cells increases with the progression o f  
histology. The aneuploidy o f  chromosome 1 is greater in the normal gastric 
mucosa(aneuploidy -2.75%) compared with the aneulpoidy levels in the normal 
oesophageal mucosa(aneuploidy -2.16%). 24 patients had H. pylori negative gastritis 
and the anueploidy levels in them were 3.78% compared with aneuploidy levels of 
5.74% in the 8 H .pylori positive patients and this was significant(p-0.03).The 
aneuploidy levels in the patients with intestinal metaplasia(n=4) was 7.28 and this was 
significant compared to the patients with gastritis(p=0.01).
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Aneuploidy in chromosome 1 was non-significantly higher in normal gastric 
tissue compared with the normal oesophageal tissue (p<0.200). Chromosome 1 
abnormality was higher in patients with gastritis (p<0.0381) and this was significantly 
abnormal in H. pylori associated gastritis (p<0.01) compare to normal gastric tissue. 
Aneuploidy levels of chromosome 1 were significantly higher in intestinal metaplasia 
group compared to normal gastric mucosa (p<0.001). The difference in chromosomal 
abnormality level increased with each successive step of Correa’s pathway, with highest 
percentage of abnormality was seen in the intestinal metaplasia stage
3.3 Discussion
The experiments described in this chapter were aimed at studying chromosomal 
abnormalities present in gastric tissue in vivo, using inter phase FISH, to investigate the 
hypothesis that as the histological progression occurs in the development of gastric 
cancers, there is also an increase in the genetic abnormalities leading to an increase in 
the aneuploidy levels. Inter phase FISH was successfully used to determine this. The 
level of aneuploidy of chromosome 1 increased as the histology progressed through the 
well established Correa’s pathway.
As explained in chapter 2, the patients were enrolled during their routine 
appointments for upper GI endoscopy at the Neath Port Talbot hospital and Royal 
Glamorgan Hospital, and therefore no selection policy was adopted in recruiting them 
into the study. Same procedures were adopted in both the hospitals to recruit the patient. 
They were patients referred by their medical practitioners for varying reasons. An 
information leaflet regarding the study and consent forms were posted to them in 
advance and any questions were answered by the well trained endoscopy nurses or by 
me. A maximum of 2-3 patients were enrolled in the study in a list as there were time 
constraints on a busy open access endoscopy lists. We did not screen the patients prior 
to the endoscopy as this would have involve the patient making an additional prior visit 
to the hospital. The suitability of the patients was assessed during their admitting 
process in to the unit and a brief clinical questionnaire was given to them to be filled in. 
Information regarding their risk factors were obtained to ascertain if any of the risk
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factors were significant and corresponded to the aneuploidy levels. This information 
was collected from the patients and we did not seek corroborative evidence for this by 
either looking through their medical notes or liaising with the referring doctor. A note of 
all medications was obtained if the patients had their list of medications with them. The 
accuracy of the information has to be questioned as we did not seek to confirm the 
information provided by the patients and we are aware that this could have resulted in 
underreporting of risk factors. Interviewing the patients prior to their endoscopy date 
and allowing more time for the questions would have resulted in improved accuracy but 
again this could have not been possible due to the constraints on the time and resources.
Solid tissue has often proven to be difficult to manipulate into a form required to 
perform FISH techniques. A single layer of cells need to be produced so that FISH 
probes can be added, and then detected in the nuclei of these cells using microscopy. 
Therefore, in this study the most important step was to make sure that the cells collected 
were delivered so that they were suitable for FISH. Modification of techniques 
described by Doak et al (2003) has shown that cytology brushings from endoscopy is a 
reliable and safe method of cell collection for this purpose. It also allows adequate cells 
to be spun onto a microscope slide to form a cytodot to perform FISH in these samples. 
Inter phase FISH is an observer dependent technique and the technique improved 
considerably with my experience. Gastric biopsies were taken from the same site and 
they were used to determine the histological stage, CLO test to determine the H. pylori 
status and also to extract the RNA to perform gene expression levels of MAD2 and 
BUB1 genes as explained in chapter 2. In order not to prolong the procedure, gastric 
biopsies were taken only from one site as the risk of complications associated with the 
procedure increases with increased endoscopy time. As previously explained in chapter 
2, brushing of the gastric mucosa precede the biopsies to avoid red blood cells in the 
cytology samples. The gastric biopsies were taken just adjacent to the site of the gastric 
brushings. The samples were obtained from the gastric antrum if the gastric mucosa 
appeared normal during the endoscopy but otherwise the samples were collected from 
the abnormal site.
Using these cell preparations, our aim was to determine the level of aneuploidy
present in the pre-malignant gastric tissue samples from the enrolled patients. The
chromosome targeted has been implicated in the development of gastric and
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oesophageal adenocarcinomas. A variety of histological stages (i.e., normal, gastritis, 
intestinal metaplasia) were obtained for the purpose of the study and all of them fitted 
into the early stages of multi-step model proposed by Correa in the development of 
gastric cancers.
Initially, a comparison was made of normal oesophageal and gastric tissue from 
the same patients. The normal squamous oesophageal mucosa had very small amount of 
aneuploidy in chromosome 1 when compared with normal gastric mucosa. The level of 
aneuploidy in the normal gastric mucosa was non-significantly higher (P<0.2) when 
compared with the normal oesophageal mucosa. This is comparable with the results 
shown by Williams et al (2005).
Histologically, normal gastric tissue showed increased aneuploidy and this may 
be explained by the different environments in which these two tissues exist in vivo. 
Gastric cells are bathed in gastric acid, an acidic medium and often contain bile 
regurgitated from the small intestine, food, mucus, enzymes and bacteria (H. pylori). 
The oesophageal mucosa comes into contact with these only during brief reflux episode. 
Bile and acid have been implicated in the pathogenesis of upper GI tract cancer 
(Triadafilopoulos 2001). Bile acids have also been shown to cause DNA damage 
(Scates et al. 1996,, D K Scates et al. 1996) and are also implicated in the development 
of chromosomal abnormalities (Jenkins GJ et al 2007).
Against the unstable background found in the gastric tissue, specific 
chromosomal abnormality was sought. Chromosomal abnormalities occurring at 
varying stages of gastric cancer pathogenesis have already been discussed. 
Abnormalities in chromosome 1 occur early in the pathogenesis and the chromosomal 
aberration expands in a stepwise manner with cancer progression (Kitayama et al. 
2000). Chromosomal abnormalities of 1 and 17 were shown to be high in the tumours of 
the gastric cardia, suggesting high instability at this particular site (Fringes et al. 2000). 
In addition to the above mentioned chromosomes, various others are implicated in the 
pathogenesis of gastric tumour. Beuzen et al (2000) have shown that there is high 
frequency of chromosomal numerical aberrations in oesophageal and gastric
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adenocarinomas, without differences between adenocarcinomas of the gastric cardia and 
the gastric antrum.
Abnormalities of chromosome 20 have been showed to be associated with the 
development of adenomas as well as carcinoma (Panani, Roussos 2005), a stage further 
along than gastritis and intestinal metaplasia. Chromosome 4 aneuploidy has also been 
shown to progressively increase as the histology progressed. Chromosome 4 
amplification has been shown to be significant in the progression of disease from 
Barrett’s oesophagus and to adenocarcinomas (Doak et al 2003, Croft et al 2002). 
Amplification of chromosome 4 has been shown to be significantly increased in patients 
with H. pylori induced gastritis and has been thought to play an important role in the 
development of H. pylori induced gastric cancer (Williams et al. 2005). Chromosome 4 
was studied in 52 of the 61 samples in the study but the data could not be used as the 
binding of the CEN probe for chromosome 4 was non -specific.
This study has reinforced the concept that interphase FISH can be easily 
employed to monitor aneuploidy when used in conjunction with brush cytology. It has 
also been shown that the cells in the brushes can be retrieved even after a day from the 
day of the procedure. Thirty four of the sixty four samples from Neath Port Talbot 
Hospital yielded good quality cells for this study. The degree of aneuploidy may have 
been underestimated in this study as only one chromosome was studied. Chromosome 1 
was chosen due to the reports that it is particularly implicated in the gastric cancer 
(Kitayama et al. 2000, Fringes et al. 2000). It would have been apparent that aneuploidy 
levels are even higher if we have studied more chromosomes in the premalignant 
tissues. Our group have previously studied chromosome 4, 8, and 20 and these have 
been found to have similar overall levels of aneuploidy i.e., 2-3% of normal gastric cells 
and 7-10% of intestinal metaplasia. Nevertheless, some underestimation is expected if 
only one chromosome is studied.
Given that chromosome 1 aneuploidy levels correlate well with the histological 
progression, it is possible that this genetic event is causatively linked to the 
carcinogenesis, or alternatively that it is the marker for the aneuploidy per se, and that
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aneuploidy is co- incidentally linked to carcinogenesis. It is difficult to envisage that the 
12% aneuploidy levels encountered in the advanced stage of the Correa’s pathway is the 
only cause for the neoplastic progression. It is more likely that they represent a state of 
chromosomal imbalance which occurs in the premalignant tissue. This is supported by 
the previous work performed by our group involving chromosome 4, 8 and 20. It is 
becoming clear that chromosome instability occurs early in carcinogenesis and this 
provides a heterogeneous pool of clones for tumour evolution to select from.
Interestingly, the gastric tissue appeared to be genetically unstable. Aneuploidy 
levels were not only higher in the inflamed gastric tissue but also in the normal gastric 
tissue than in normal oesophageal tissue analysed alongside. The aneuploid levels in 
normal gastric tissue (2.37%) was higher when compared to the normal oesophageal 
tissue (2.2%), which were seen in 4/8 patients. When comparing the aneuploidy levels 
in the gastric IM tissue to the Barrett’s oesophageal tissue (this represents the similar 
histological stage), they were 4 fold greater in the stomach (6.32% Vs 2.31%). This was 
also seen in a previous study performed by our group (Williams et al 2005) and 
probably reflects the harsh environment in the stomach (acidity, bile acids, certain food, 
nitrosamines).
There was an apparent trend for males having advanced histology (29 males
patients had gastritis or intestinal metaplasia or atrophy compared with 21 female
patients, 4 out of 5 patients with intestinal metaplasia or atrophy are males).This was a
confounding factor when the correlation between the aneuploid level and age and sex
was sought. The higher aneuploid levels in men was probably complicated by the fact
that the males tended to dominate the later histological subgroup and hence tended to
have higher aneuploid levels, as these were correlated with the histology. This was also
true in the case of the age as the number of older patients were also higher in later
histological group. The mechanism of the sex bias in gastric cancer is unknown, but
may be due to the effects of differing sex hormones. A recent study has shown that
hormone replacement therapy (HRT) led to a 50% reduced risk of gastric cancer,
suggesting that the female sex hormones may protect against this form of cancer (
Lindblad et al 2005, Chandanos and Lagergren 2008). Conversely, it has been shown
that tamoxifen which blocks the oestrogen receptor might be implicated in the
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development of gastric non cardiac tumours (Chandanos et al 2006). More work is 
obviously needed to further unravel the exact mechanisms involved and to establish if 
oestrogens can ameliorate the molecular causes of gastric cancer, like aneuploidy.
Interestingly, there was a 40 year old female patient in the study with significant 
family history of gastric cancer and with significant aneuploid levels for chromosome 
1(5.7%) and had gastritis, who would probably benefit from regular surveillance. H. 
pylori are associated with gastric cancer pathogenesis (Hansson et al. 1993) and her H. 
pylori status is unknown and would possibly benefit from eradicating it. There is no 
national surveillance guideline for these patients in this country. Identifying these 
patients and using aneuploidy levels as a biomarker in assessing their progression is a 
possibility but larger prospective studies which can follow these patients for a longer 
length of time would be required. As there is no current evidence to follow these 
patients, she will be treated as per the current practice of treating her symptoms with a 
proton pump inhibitor and a standard triple therapy of a proton pump inhibitor and two 
antibiotics. These patients are not regularly checked for the eradication of H. pylori by 
the treatment. This can be performed by using a urea breath test. Urea breath test to 
confirm the eradication of H. pylori is only offered for patients with persistent 
symptoms in spite of the treatment.
Long term non steroidal anti inflammatory use is associated with reduced risk of 
gastric cancers (Lindblad et al. 2005). It was interesting that we did not notice an 
increase in the aneuploid levels in patients taking non steroidal anti inflammatory 
medications. As mentioned above, the number of patients taking the medications was 
low, the information was collected from the patient prior to the endoscopy and the 
information was not cross checked, the duration of NSAID use was not known.
The aneuploidy level in the gastric epithelium might represent a useful 
biomarker for neoplastic progression in the stomach and may be indicative of the risk of 
cancer development. Therefore monitoring this biomarker might be clinically useful. 
Obviously, close follow up of this particular cohort of patients and the correlation of 
cancer incidence with aneuploidy is needed to strengthen this link. Using an accepted
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method of identifying “aneuploid” patients as those with aneuploidy that was two 
standard deviations higher than the normal patients, 16 out of 61 patients in this study 
are classified as “aneuploid”. This approach may help in selecting patients for closer 
follow up. New evolving methods such as automated scoring of chromosome copy 
number by image analysis are promising in making this possible. This kind of 
automated approach will help us in monitoring large number of patients and may 
represent an effective patient monitoring strategy.
Chapter 4 will look at the gene expression levels of MAD2 and BUB1 genes and 
will correlate this with the histological progression along the Correa’s pathway. A 
correlation between the gene expression levels of MAD2 and BUB1 will be sought 
against the aneuploid levels as well. These spindle check point genes are implicated in 
the development of aneuploidy.
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CHAPTER 4
The analysis of the gene expression levels of MAD2 and BUB1 levels in
the gastric premalignant tissues
4.1. Introduction
Mitotic check points have various components which are involved in evoking a 
cascade response to any defect in spindle cell assembly, preventing the progression of 
the cell cycle to anaphase. It is a highly regulated feedback mechanism that plays an 
important role in maintaining the genetic stability and integrity. MAD2 and BUB1 are 
the most commonly studied genes as they play an important role in the mitotic check 
point. Mutation of these genes and altered expression levels are reported in breast, lung, 
colon and gastric cancers (Ouyang et al 2002, Myrie et al 2000, Shigeshi et al 2001, and 
Tanaka et al 2001).
The experiments described in this chapter looked for the gene expression levels 
of MAD2 and BUB1 levels in the gastric biopsy tissue samples obtained from the 
patients at the Neath Port Talbot Hospital using the methodology described in chapter 2. 
These were the same patients for which aneuploidy level was also assessed in Chapter
3. MAD2 and BUB1 expression levels were sought as they are the most commonly 
altered genes (within the spindle check point pathway) in many aneuploid cancers as 
described earlier. The steady state levels of mRNA of both MAD2 and BUB1 were 
quantified in all the premalignant gastric cancer stages, using real time RT-PCR. These 
gene expression levels were then correlated with clinical parameters for the patients and 
with the level of aneuploidy, which was assessed using FISH, as described in chapter 3, 
in order to determine if alterations in the expression levels of MAD2 and BUB1 mitotic 
spindle checkpoint genes were involved in inducing chromosomal instability in the 
samples studied.
103
4.2 Data Analysis
Real time RT PCR reaction is explained in detail in chapter 2. Real time PCR 
was performed with each primer set required for the study on a serial dilution (neat, 1 in 
10, lin 100, 1 in 1000) from each of the cDNA samples. This was repeated at least 
twice and the transcription levels of MAD2, BUB1 and p Actin were calculated. The 
mean expression levels of MAD2, BUB1, and p Actin, from these two RT PCR 
reactions were calculated. This value was used in the analysis to look for correlation 
between age, smoking habits, aneuploidy levels. This value is represented on the Y axis 
in this chapter.
4.3 Results
4.3.1 Differences in MAD2 and BUB1 level between men and women
Forty four patients were enrolled in the study and of them, 25 were female and 
19 were male. There was no significant difference (MAD2 p value - 0.26/BUB 1 value
0.71) in the expression levels of MAD2 and BUB1 between them.
Figure 4.1 shows the difference in the expression levels of MAD2 and BUB1 in 
different sex.
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Figure 4.1 MAD2 and BUB1 expression levels in males and females
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Fig 4.1 Twenty five female patients had an average MAD2 expression level o f  1.37 and 
BUB1 expression level o f  0.90. 19 male patients had an average MAD2 expression 
levels of 1.11 and BUB1 expression levels o f  0.80. There was no significant difference 
between the MAD2 levels (p=0.26) or BUB1 levels (p=0.71) between males and 
females.
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4.3.2 Differences in MAD2 and BUB1 level depending on the H. pylori status
Infection with H. pylori was confirmed either by performing a CLO tests during 
the endoscopy or by histology. All stages of histology described by Correa were 
represented in these samples used to analyse the MAD2 and BUB1 expression levels.
Eighteen patients were negative for H. pylori and six patients were positive for 
it. The H. pylori status was unknown for the rest of the patients. There was no 
significant difference in the expression levels of MAD2 and BUB1 depending on their
H. pylori status (MAD2 p value -  0.09/BUB 1 p value -  0.71).
Figure 4.2 explains the differences in the MAD2 and BUB1 levels in patients with H. 
pylori infection.
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Figure 4.2 MAD2 and BUB1 expression levels based on CLO results
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Fig 4.2Eighteen patients were CLO negative and six patients were CLO positive.MAD2 
expression levels were 1.29 and 1.86 between CLO negative and CLO positive patients 
respectively and there was no statistical difference between them(p=0.09). BUB1 
expression levels were 1.18 and 0.98 between the CLO negative and CLO positive 
patients respectively. There was no significant difference in their expression levels 
(p=0.71)
Although the MAD2 expression levels did not reach the significant levels 
between the patients with or without H. pylori infection, the p value o f  0.09 suggests 
that the infection could cause some alteration o f  MAD2 levels.
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4.3.3 Differences of MAD2 and BUB1 level and significant aneuploid levels
MAD2 and BUB1 expression levels were correlated with significant aneuploidy 
levels. The value of aneuploid level, which is 2 standard deviation above the aneuploid 
levels seen in patients with normal histology was taken as ‘significant aneuploid’ levels. 
The value used was 4.86 % and the method which was used to determine this is 
explained in chapter 3. There was no difference in the MAD2 or BUB1 expression 
levels in patients with significant aneuploidy. The difference in MAD2 and BUB1 
levels did not reach the level of significance between patients with significant 
aneuploidy(4.86%) when compared with patients who did not have significant 
aneuploidy(MAD2 P value 0.30 and BUB1 p value 0.07). The patients with aneuploidy 
but whose aneuploidy levels did not reach the significant levels was combined with the 
patients in whom the aneuploidy levels did not reach the ‘cut o ff of 4.86%.
Figure 4.3 shows the expression level of MAD2 and BUB1 in patients with significant 
aneuploidy.
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Figure 4.3 MAD2 and BUB1 levels in patients with significant aneuploidy
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Fig 4.3 Six patients had aneuploidy levels above the significant aneuploidy level cut off 
o f  4.86%. MAD2 expression level were 1.23 and 1.156 in patients below and above the 
significant aneuploidy levels (p=0.93) and BUB1 levels were 0.75 and 0.76 in patients 
below and above the significant aneuploidy levels(p=0.98).
samples be low  sign ificant 
aneup lo idy levels
samples above sign ificant 
aneup lo idy  levels
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4.3.4 MAD2 and BUB1 expression levels in patients with family history of 
upper gastrointestinal cancers
Six patients had family history of upper GI cancers. In both the sub sets there 
was a mixture of histological stages ranging from normal histology to intestinal 
metaplasia. There was no statistically significant difference in the expression levels of 
MAD2 and BUB1 gene in patients with family history of upper gastrointestinal cancers 
when compared with patients with no family history (MAD2 p value -0.45/BUB 1 p 
value -0.55).Although the results did not reach statistical significance, there was a clear 
decreasing trend in the expression of MAD2 and BUB1 levels in patients with the 
family history of upper gastrointestinal cancers.
Figure 4.4 shows the expression level of MAD2 and BUB1 in patients with family 
history of upper GI cancers.
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Figure 4.4 MAD2 and BUB I levels in patients with family history o f  upper GI cancers
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Fig 4.4 Six patients had significant family history. The MAD2 levels were 0.76 and 
1.34 in patients without any history of  upper gastrointestinal cancers and with history of 
upper gastrointestinal cancers (p=0.45). The BUB1 levels were 0.62 and 0.94 in patients 
without any history o f  upper gastrointestinal cancers and with history o f  upper 
gastrointestinal cancers (p=0.55).
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4.3.5 MAD2 and BUB1 expression levels and smoking habits
Of the forty four patients, nine were smokers and there was no significant 
difference in the MAD2 expression levels between the two subgroups (p value MAD2 -
0.53). BUB1 expression levels were 0.46 and 0.41 in smokers and non smokers 
respectively (p value -  0.78).
Figure 4.5 represents the difference in the levels of MAD2 and BUB1 between the 
smokers and non smokers.
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Figure 4.5 MAD2 and BUB1 levels in smokers and non smokers
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Fig 4.5 Nine smokers and thirty three non smokers were identified in the study. The 
MAD2 levels were 1.32 and 1.17 in smokers and non smokers respectively 
(p=0.55).The BUB1 levels were 1.43 and 0.89 in smokers and non smokers respectively 
(p=0.05).
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4.3.6. MAD2 and BUB1 expression levels according to the age
Correlation coefficient was calculated for MAD2 and BUB1 expression levels 
and age of the patient. The correlation efficient for MAD2 level was -0.11 and for 
BUB1 was 0.08. There was no significant positive or negative correlation between the 
gene expression levels and the age.
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Figure 4.6a represents the differences between MAD2 levels in the different age group
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Figure 4.6a and b Shows the MAD2/BUB1 expression levels on the x axis and the age 
o f  patients at endoscopy on the y axis. There was no significant correlation between the 
age o f  the patient and the MAD2/BUB1 expression levels
Figure 4.6b represents the differences between BUB1 levels in the different age group
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4.3.7 MAD2 and BUB1 expression levels and histology
Eleven patients had normal gastric histology and twenty eight patients had 
chronic gastritis, of which four was H. pylori associated gastritis and four patients had 
intestinal metaplasia. There was no significant difference in the MAD2 expression level 
between patients with normal histology and gastritis (p value -  0.13) and between 
patients with normal histology and intestinal metaplasia (p value -0.45). There was also 
no significant difference between the levels of BUB 1 expressed by patients with normal 
histology and gastritis (p value -0.12) and between patients with normal histology and 
intestinal metaplasia (p value -  0.47)
Fig 4.7 describes the MAD2 and BUB1 level in the normal, Gastritis; H. pylori 
associated gastritis and intestinal metaplasia.
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Figure 4.7 MAD2 and BUB1 levels depending on the histology
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Fig 4.7 Twenty two patients had H. pylori negative gastritis, four patients had H. pylori 
associated gastritis and four patients had intestinal metaplasia and the rest were o f  
normal histology . The MAD2 levels were 1.55 and 1.11 in patients with normal 
histology and H. pylori negative gastritis (p=0.49). The BUB1 levels were 1.49 and 0.62 
in patients with normal and H. pylori negative gastritis (p=0.73). MAD2 and BUB1 
levels were decreased in H. pylori associated gastritis (MAD2 -1.81 and BUB1 level- 
1.07) and this did not reach any significance (p=0.85).MAD2 and BUB 1 levels were 
decreased again in the intestinal metaplasia stage (MAD2-0.82 and BUB 1-0.43), this 
also did not reach any statistical significance (p=0.63).
But there was significant increase in the levels o f  MAD2 and BUB1 between patients 
with normal histology and patients with H. pylori associated gastritis (MAD2 p value -
0.01 and BUB1 p value -  0.01)
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4.4 Discussion
The experiments described in this chapter have attempted to study the gene 
expression levels of MAD2 and BUB1 in the gastric tissue, using real time RT -PCR 
and to investigate the hypothesis that as gastric carcinogenesis progresses, so does the 
genomic instability. The genomic instability is probably driven by the defects in the 
spindle check points. We studied MAD2 and BUB1 genes as they play a very important 
role in the pathogenesis of gastric cancer. There are studies, which has demonstrated 
that over or under expression can occur, leading to the premature entry into anaphase 
(Grabsh et al 2003, Tanaka et al 2001).
As explained in the chapter 3, the patients were enrolled from my routine open 
access endoscopy at Neath Port Talbot Hospital, and as a result no selection process was 
applied in recruiting them in the study. The cohort of patients enrolled in the study 
reflects the population of patients with upper GI symptoms, who were referred by the 
general practitioners in that region. A maximum of 2-3 patients were enrolled in the 
study per list. This was due to the time constraint on a busy endoscopy list. The patient 
selection could have been performed, but this would have required patients to have a 
prior additional visit and this was again restricted by the time and resources. The 
patients were interviewed on arrival by an experienced endoscopy nurse and a clinical 
questionnaire regarding their family history, smoking and dietary habits, alcohol intake 
and drug intake was obtained. This information was not corroborated by checking them 
in their clinical notes or with their general practitioners as this would be time 
consuming.
MAD2 and BUB1 expression levels were studied in a large group of patients 
(n=44). They represented the patient cohort most likely to be seen in the community as 
they were referred by their general practitioners. The number of patients with intestinal 
metaplasia was small (n=4) but again there was no way of improving this as it is 
difficult to predict the histology of the patients depending on their symptoms or by the 
endoscopy appearances.
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Recent studies have looked at the BUB1 levels in the gastric cancers and also 
the looked at the DNA ploidy levels in the gastric tissue (Grabsch et al. 2003, Grabsch 
et al 2004). It has been demonstrated that over expression of BUB 1, BUBR1 and BUB3 
occurs in diffuse type gastric cancer when compared with the intestinal type gastric 
cancer. Kim H et al (2005) study of gastric cancers and gastric cancer cell lines showed 
that frequent mutation of MAD2 genes but not BUB1 caused functional defects in 
spindle checkpoints, which could lead to the development and progression of gastric 
cancers.
MAD2 expression levels were also studied using the same samples. A steady 
state level of MAD2 is thought to be important in maintaining the integrity of the 
spindle cell checkpoint and is recruited as a part of the complex in preventing the cell 
from progressing to anaphase. This study looked at the MAD2 and BUB1 expression 
levels in all the stages preceding the development of gastric cancers and also looked at 
their correlation with the aneuploidy levels in the premalignant gastric tissue.
In this study, there was no correlation with the level of significant aneuploidy 
and the level of the MAD2 and BUB1 expression levels. Although, the intention was to 
look for the aneuploidy levels in chromosome 1 and 4, only the results from 
chromosome 1 could be analysed as the signals from chromosome 4 was non-specific. 
This decreases the sensitivity of the study. Aberrations of chromosome 1 were seen in 
gastric cancer especially in the early stages of gastric cancer.MAD2 gene is in 
chromosome 4 and therefore it would have been interesting to have seen the aneuploidy 
levels of chromosome 4 as well as chromosome 1. It could be postulated that the 
aneuploidy occurs early in the pathogenesis and this leads to cumulative loss of 
particular genes, which encodes the mitotic checkpoint components, which result in 
over or under expression of MAD2 and BUB1 levels. Again the number of patients with 
significant aneuploidy (more than two standard deviation of the aneuploidy seen in 
normal patients) was low. A larger study looking at other chromosomes in addition to 
the chromosome 1 would provide us with better answer to this question in the future.
119
The expression levels of MAD2 and BUB1 was not affected by increasing age, 
or differences in the gender, family history of upper GI cancers or the presence of 
significant aneuploidy.
Smoking has been directly implicated in the development of various cancers 
E.g., lung, and bladder cancers. The studies looking at the genetic alterations caused by 
smoking are rare. Lin et al (2010) have shown that smoking caused abnormalities of K 
ras and P53 genes in small and non small cell lung cancer. Although there was no 
statistical difference in the levels of BUB 1 and MAD2 levels between the smokers and 
the non smokers, in this study, It would be interesting to look at various other potential 
genetic alterations that could be caused by smoking and this could contribute to our 
better understanding of the mechanism involved in the tumour initiation and progression 
by smoking.
This study has shown that the MAD2 and BUB1 levels were significantly raised 
in patients with H. pylori associated gastritis. This demonstrated that the most important 
changes may occur due to the H. pylori infection and H. pylori infection may act trigger 
a cascade of events responsible for the progression to precancerous intestinal metaplasia 
stage.
4.4.1 Epigenetics and Cancer
Classic genetics does not explain the variation in phenotypes within a 
population. It does not explain why there are different phenotypes and different 
susceptibilities to a disease despite their identical DNA sequences. Epigenetics provide 
a partial explanation to this. C.H Waddington (1939) introduced this concept and 
epigenetics was defined later as heritable changes in gene expression that are not due to 
any alteration in the DNA sequence (Holliday 1987).
Epigenetic changes are generally categorised into four areas: DNA methylation, 
histone modification, chromatin remodelling and miRNAs (Estellar 2006).DNA 
methylation play an important role in the control of gene activity and the architecture of
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the nucleus of the cell. In humans, DNA methylation occurs in cytosines that precede 
guanines; these are called dinucleotide CpGs. (Herman 2003, Weber 2007). CpG sites 
are not randomly distributed in the genome; but there are CpG-rich regions known as 
CpG islands, which span 5’ end of the regulatory region of many genes. These islands 
are not methylated in normal cells (Herman 2003, Weber2007).The methylation of 
particular subgroups of promoter CpG islands can be detected in normal tissues. 
Significant nuclear abnormalities are detected as a result of spontaneous defects in 
DNMTs (DNA methyl transferase) (Xu1999) or experimentally induced DNMTs 
(Espada2007).
One of the first epigenetic alterations found is the low level of DNA methylation 
found in tumours as compared with the level of DNA methylation in the normal tissue 
(Feinberg 1983). The low level of methylation is mainly due to the hypomethylation of 
repetitive DNA sequences and demethylation of coding regions and introns -  regions of 
DNA that allow alternative versions of the messenger RNA that is transcribed from a 
gene(Feinberg 2004). During the carcinogenesis, the degree of hypomethylation of 
genomic DNA increases as the lesion progresses from a benign proliferation of cells to 
an invasive cancer (Fraga 2004). There are three ways that are proposed to explain the 
contribution of DNA hypomethylation in the development of cancers: generation of 
chromosomal instability, reactivation of transposable elements, and loss of imprinting. 
Low levels of DNA methylation can favour mitotic recombination, leading to deletions 
and translocations and can also promote chromosomal rearrangements.(Eden 2003) .It 
has been shown in experiments that disruption of DNMTs causing low levels of DNA 
methylation can cause aneupoidy (Karpf2005).
Hypermethylation of CpG -  island promoter can affect the genes that are 
involved in the cell cycle, DNA repair, the metabolism of carcinogenesis, cell-to-cell 
interaction, apoptosis, and angiogenesis, all of which are involved in the development of 
cancers (Baylin 2005, Correa 1994). The profiles of hypermethylation of the CpG 
islands in tumour suppressor genes are specific to the cancer type (Costello 200, Estellar
2001). Each tumour type can be assigned a specific, defining DNA “hypermethylation”
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and this can not only be seen in the sporadic cancers but also in inherited cancer 
syndromes(Estellar2001).
Histone modification can occur in different histone proteins, histone variants, 
and histone residues such as lysine, arginine, and serine. This can involve various 
chemical groups e.g., methl, acetyl, and phosphate groups. The degree of modifications 
can also for e.g., mono, di, or tri methylation. There are different permutations and 
combinations that result in complex array of histone modifications. These 
modifications affect a variety of nuclear processes like gene transcription, DNA repair, 
DNA replication, and the organisation of chromosomes. Hypoacetylation of histone is 
usually associated with transcriptional activation (Mack2006, Berenstein2007). The 
effect of histone methylation depends on the degree and also on the type of amino acid 
involved (Mack2006, Berenstein2007).These changes appear early and accumulate 
during the development of cancer (Mack2006).
The miRNAs are non coding RNAs that regulate gene expression by sequence- 
specific base pairing in the 3 ’ untranslated regions of the target RNA. The miRNAs are 
tightly controlled and they play an important role in the cell proliferation, apoptosis, and 
differentiation (He 2004).The knowledge of the human genes that lose activity due to 
the attached of a miRNA to the translated regions in increasing (He 2004,Chen2005). 
The profiles of miRNA expression differ between normal tissues and tumour tissues and 
among tumour types (Chen 2005, Cailin2006, Lu 2005).
The DNA methylation and histone modification can be used in the cancer 
management. DNA hypermethylation markers has a potential to be used as a 
complimentary diagnostic tool, prognostic factors and in the estimation of cancer 
response to the treatment for e.g., 80-90% of patients with prostate cancers have 
hypermethylation of glutathione S transferase gene (GPSTPl)(Leel994,
Estellarl 998,Caims2001),hypermethylation of the death- associated protein 
kinase(DAPK), pl6ink4a epithelial membrane protein 2(EMP3) has been linked to poor 
outcomes in lung, colorectal, and brain cancer respectively (Estellar 2007). DNA 
methylation and histone modifications are reversible. It is possible to re express DNA
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methylated genes in cancer cell lines by using demethylating agents (Estellar 2008) 
Low dose DNA demthylating drugs like 5-azacytidine (Vidadza) and 5 -aza-2’ -  
deoxycytidine(decitabine) have been approved in the treatment of leukemia and 
myelodyplastic cancers(Estellar 2008).
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CHAPTER 5
General discussion
Gastric carcinoma is one of the major health burdens worldwide and a common 
cause of cancer related death in the world (Jeon 2010). Although the incidence of 
gastric cancer is gradually decreasing in the developed world, its incidence is still high 
in certain parts of the world. It is thought to be due to the difference in the 
socioeconomic conditions and is also related to the prevalence of H. pylori infection. 
The incidence of gastric cancer varies even among different regions in the same 
Country. The prevalence of H. pylori infection is gradually decreasing in certain 
countries like United Kingdom and Japan. Gastric cancers are diagnosed late and as a 
result of this has an increased mortality. In Japan, where the incidence of gastric cancer 
is high, there is an endoscopic surveillance programme, which helps in detecting the 
cancers at an early stage. This has lead to improved survival rate in this country. Correa 
described a multistep pathway in the pathogenesis of gastric cancer. As there are several 
histologically identifiable premalignant stages and the lesion is easily accessible, 
changes in gastric mucosa is an ideal human research model for investigations into the 
underlying genetic basis for the development of gastric cancer. The research interest has 
grown in this particular aspect as prognostic markers are needed to determine those 
patients at greater risk for developing the malignancy. The development of these 
markers would help us to stratify the patients into a high risk/ low risk groups for cancer 
and would help us in streamlining the use of health resource for example- high risk 
patients could undergo intensive surveillance programme. Currently, the pathogenic 
events associated with the development of gastric cancer are complex with wide range 
of chromosomal abnormalities implicated (Uchida M 2010,BuffartTE et al 
2009,Sanchez- Perez et al 2009).
Understanding this complex genetic process would help us in predicting the 
subgroup of patients who has progressive disease and also in designing treatment 
targeting a particular stage of the pathway to arrest its progression or even reverse the 
changes concurred by these tissue. The general aim of this thesis was therefore to 
contribute to the molecular data to the gastric cancer pathogenesis model and hopefully
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to define when specific abnormalities arise and become prominent. Hence, the 
chromosomal aberration was studied in all the premalignant histological stages of 
gastric cancer development
The initial investigation was intended to characterise when, during the 
histological progression of the gastric cancer pathway, certain chromosomal alterations 
first appeared. FISH was the technique of choice, as it involves study of single layer cell 
analysis and therefore has a sensitivity to detect low frequency abnormalities, which is 
present in the premalignant lesions. There are number of ways the cytogenetic 
abnormalities could be studied and some of them have been tested in our lab with not 
very good yield of cells. Although there are several methods available to study the 
chromosome aberrations, the use of endoscopic cytology brushes to exfoliate gastric 
epithelial cells during the upper GI endoscopy was adopted. This was mainly due to the 
fact that this method has been used successfully in our unit by Doak and Williams in the 
past and was found to be reliable and sensitive. Following several washing steps, cells 
were deposited onto slides using cytospin and their cytoplasm was partially digested if 
necessary by the treatment with pepsin to allow the FISH probe penetration. This 
procedure allowed consistent generation of suitable interphase preparation for 
subsequent FISH analysis. Brushings from the gastric mucosa posed various challenges 
as the angle of the gastric mucosa was difficult to do the gastric brushings and also the 
fact that the environment in the stomach is hostile with bile, gastric acid and food 
residue present in the stomach, which could lead to the digestion of cells. This was 
improved by washing the gastric mucosa with 5-10ml of sterile water if necessary 
before using the brush during the endoscopy. The yield of cells improved as the study 
progressed and there are several factors which may have contributed to this, for example 
increase in the experience of the endoscopy nurses helping during the procedure, change 
in the transport medium from ethanol to ETN buffer, decreasing the time of pepsin 
exposure during the pepsin treatment. As a result of the above mentioned factors, the 
yield of cells was good even after twenty four hours. The cell preparation, fixation and 
the actual method of FISH is explained in detail in chapter 2. Following this, 
centromeric probes for chromosomes 1 and 4 were used to determine the chromosomal 
aberrations of these chromosomes in the premalignant stages.
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In the second part of this study, MAD2 and BUB1 expression levels in all the 
premalignant stages implicated in the pathogenesis of gastric cancer were studied. 
MAD2 and BUB1 are important genes in the control of mitotic spindle cell check point. 
The spindle cell check point is a very well regulated feedback mechanism which 
prevents the cells from progressing from the metaphase to anaphase if a chromosome 
lacks bipolar attachment of a spindle. The unattached kinetochore generate signal which 
triggers a cascade of events, which help in preventing the progress to anaphase. 
Alterations in the gene expression levels of BUB 1 gene has reported in various tumours 
like breast cancers (Myrie et al. 2000) and colorectal cancers (Shichiri et al. 2002). 
Recent studies have looked at BUB1 genes in the gastric cancers and have found out 
that the BUB1 levels are significantly higher in patients with diffuse type gastric cancer 
when compared with the intestinal type gastric cancer (Grabsch et al. 2004). Over 
expression of BUB1 has been shown to be associated with increased proliferation of 
gastric cancer (Grabsch et al. 2003). Over expression of MAD2 has been observed in 
gastric cancer (Tanaka et al. 2001) but this did not correlate with aneuploidy, clinical or 
pathological features (Wu et al. 2004). Mutation of MAD2 has also been noted in the 
gastric cancer which could lead to the development and progression of gastric cancer (H 
(Kim et al. 2005).
Several studies have looked at various gene expression levels and the 
development of aneuploidy in different cancers. The level of Aurora Kinase A, Aurora 
Kinase B, MAD2 and BUB1 and development of aneuploidy in colorectal cancer was 
studied. This study showed that the level of BUB1 was significantly reduced in 
aneuploidy colorectal cancers when compared with diploid cancers (Burum -Auensen E 
et al 2008). In an invivo study, BUB1 function has been shown to be tension -  
dependent check point function and leading to aneuploidy and tumorogenesis 
(Schliekelman et al 2009).
MAD2 and BUB1 genes have been studied by our group in the varying
histological stages of Barrett’s oesophagus ranging from metaplasia to adenocarcinoma.
Both over and under expression of MAD2 and BUB1 levels were noticed in all the
stages of the neoplastic progression and there was no particular trend in the levels of
MAD2 and BUB1 gene expression levels. There was no correlation with aneuploidy
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implicating that other mechanism play an important role in the development of 
oesophageal carcinoma (Doak S et al 2004).
This study looked at the MAD2 and BUB1 levels in all the premalignant stages 
of gastric cancer to look for any particular trend in their levels as the disease progresses 
and also to look at the level of aneuploidy during these premalignant stages. According 
to our hypothesis, the change in the levels of MAD2 and BUB1 levels should follow a 
particular pattern with the advancing histological stage. A steady state of these genes are 
thought to be essential in maintain normal cell division and ensuring that the daughter 
cells after mitosis is a diploid cell. Over or under expression level of these genes might 
result in aneuploidy.
The gastric biopsies obtained from the same site after the gastric cytology 
brushings were used for this. Real time RT PCR was used to determine the gene 
expression levels of MAD2 and BUB1 genes. This is a sensitive method and analyses 
all fluorescent signal generated during the PCR process. SYBR green was used and this 
is an intercalated dye that binds to the minor groove of the double stranded DNA. The 
method used for analysis is detailed in chapter 4. Any defect in the mitotic check point 
leads to aneuploidy and there has been great interest in determining the exact defect in 
the spindle check point that leads to aneuploidy in cancers, which exhibit chromosomal 
instability. Gastric cancer provides a good model to study both the aneuploidy and the 
mitotic check point defect as it involves a well defined pathway in the progression to 
gastric cancer. The correlation of aneuploidy with the expression levels of MAD2 and 
BUB1 levels was performed to look at the influence the change in the expression level 
can play in the development of aneuploidy.
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5.1. Conclusion
5.1.1 Findings for chromosomal aberrations
Chromosome 1 and 4 were chosen as there has been two recent studies which 
looked at the aneuploidy levels of chromosome 1 in gastric cancer and has shown that 
the abnormality of chromosome 1 occurs independent of the gastric cancer subtype 
(Kitayama 2000) and also abnormalities of chromosome 1 was common in gastric 
cardia tumours (Fringes 2000).Chromosome 4 was studied as it has been shown that the 
amplification of chromosome 4 was shown in the development of oesophageal 
adenocarcinoma(Doak et al 2003,Williams L 2004). The findings from this study are as 
follows:
1. Aneuploidy level of chromosome 1 is higher in normal gastric tissue (2.37%) 
when compared with the normal oesophageal tissue (2.2%) and this is m this 
study thought to be secondary to the harsh environmental condition to which the 
gastric tissue is exposed.
2. The increase in the aneuploidy level of chromosome 1 progressively increased 
significantly throughout the histological progression. The aneuploidy level for 
chromosome 1 are as follows:
Histological stage Aneuploidy
level
Level of significance 
(p value)
Gatritis 3.74 0.038
H. pylori gastritis 5.055 0.015
Intestinal metaplasia 6.32 0.001
3. Elderly male patients are high risk in developing gastric cancers but this study 
did not demonstrate any significant increase in the aneuploidy of chromosome 1 
in this sub group.
128
4. There was no significant difference in the level of aneuploidy in chromosome 1 
levels between smokers and non smokers, patients on PPI and those who are not 
on PPI, patients on NSAIDs and those who do not take it.
5. Aneuploidy levels between the intestinal metaplasia stage in the stomach was 
found to be four folds higher (6.32%) when compared with the aneuploidy levels 
(2.31) in the oesophagus(Barrett’s oesophagus).
5.2. Findings of MAD2 and BUB1 expression levels
MAD2 and BUB1 gene expression levels were studied as these genes are 
considered as important genes in the mitotic check point mechanism. Biopsies from 
forty four patients were used to extract the RNA. The biopsies were frozen at 4° Celsius 
in the first 24 hours of taking the sample. RNA extraction was performed in batches and 
they were stored at -80°C in small aliquots. The RNA was thawed in batches to prevent 
frequent freezing and thawing to perform the real time PCR. The real time PCR was 
conducted according to the protocol described in Chapter 2 Materials and methods.
To our knowledge, the expression levels Of MAD2 and BUB1 have been 
studied in the gastric cancers but they have not been previously studied in all the 
premalignant stages of gastric cancer. It was also thought that the alterations in their 
expression level would correspond to the aneuploidy levels seen in the samples. The 
conclusions from this study are:
1. There was no difference in MAD2 and BUB1 levels between male and female 
patients.
2. There was no difference in the level of MAD2 and BUB1 expression levels in 
patients with aneuploidy. There was no difference in the expression level of 
MAD2 and BUB1 levels even in patients with significant aneuploidy level of 
4.86% ( as explained in the chapter 3) It must be stressed that the sensitivity of 
this study is low as only chromosome 1 was studied.
129
3. This study had six patients with family history of upper gastrointestinal cancers. 
There was a decreasing trend in the expression level of MAD2 and BUB1 levels 
although this did not reach statistical significance.
4. Although smoking is a well known risk factor for the development of upper 
gastrointestinal cancers, there was no difference in the expression of MAD2 and 
BUB1 levels between the smokers and the non smokers.
5. There was a significant increase in the expression levels of MAD2 and BUB1 
levels in patients with H. pylori associated gastritis when compared with patients 
with normal histology. There was no difference in the expression levels of 
MAD2 and BUB1 levels between patients with normal histology and chronic 
gastritis that is not associated with H. pylori infection. This stresses that the 
infection with H. pylori plays an important role in the progression of the disease
6. MAD2 and BUB1 levels were analysed in all the stages of premalignant gastric 
cancer pathways. There was no significant difference in the levels of MAD2 and 
BUB1 between normal histology and H. pylori negative gastritis. Again there 
was no statistical difference in the levels of MAD2 and BUB1 levels between 
normal histology and intestinal metaplasia. But there was significant increase in 
the levels of MAD2 and BUB1 between patients with normal histology and 
patients with H. pylori associated gastritis
5.3 Limitations of the study
The strength of the study lies in the fact that it looked at a large number of 
patients and determined their aneuploidy levels of chromosome 1 and their MAD2 and 
BUB1 expression levels and included all the premalignant stages of gastric cancer, there 
are limitations to this study and they are:
1. Although the intention of the study was to look for the aneuploidy levels in 
chromosome 1 and chromosome 4, the data from chromosome 4 could not be 
used as it was non-specific. This is one of the major limitations of the study as 
only one chromosome was studied and this does decrease the sensitivity of the 
study.
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2. The number of patients with intestinal metaplasia was low (n=4) but there is no
reliable way of predicting and increasing the number of this sub group in the 
endoscopy.
3. Patients were given questionnaires before the endoscopy to assess their risk 
factors and to get details regarding their life style e.g., smoking, alcohol intake, 
dietary habit including the number of portions of fruits and vegetable, drugs. 
This was not corroborated with their primary care physician or their medical 
records due to the constraints on the time and resources.
4. There was no difference in the expression levels of MAD2 and BUB1 levels in 
patients with aneuploidy or in patients with significant aneuploidy levels 
(4.86%) of chromosome 1. But it must be stressed that only the aneuploidy 
levels of chromosome 1 was studied due to the above mentioned reason. This 
again decreases the sensitivity of the investigation.
5.4 Expanding work -  future studies
There are number of ways this study could be taken forward and they are as follows:
1. It would be interesting to perform a follow up study in 5 years time and review 
individual phenotypic deterioration or progression in patients with significant 
aneuploidy and also the level of their aneuploidy at that time. This would help 
us in the assessment of aneuploidy as a predicator of gastric cancer.
2. There was one patient in the study who had significant aneuploidy levels and
family history of gastric cancer. It would also be interesting to follow this
patient to determine the histological progression. This could be an interesting 
case study -  on which a future detailed study could be designed in patients with 
significant family history of gastric cancer.
3. Patients who have significant aneuploidy and with later stage of histology
according to the stages described by Correa, can have their risk factors
modified -  for example testing and treating H. pylori, quit smoking, decrease 
weight and increase intake of vegetables and fresh fruits. It would be 
interesting to see what happens to their aneuploidy level, MAD2 and BUB1 
expression levels after the risk modification. This would have to be a larger
study performed over a reasonable length of time to allow for such 
modification of risk to effectively affect the aneuploidy levels.
4. The biopsy taken to determine the histological stage is normally preserved as 
paraffin embedded tissue and is available for future use if necessary. This can 
be used to determine other chromosome aberrations by other methods such as 
immunohistochemistry. This will complement this study well as it will 
increase the number of chromosomes studied in the same patients.
6. This study has shown again that the background aneuploidy level is increased in 
normal gastric tissue when compared with the oesophageal tissue. This is due 
to the unique microenvironment that exists in the stomach. It would be 
interesting to know if this is peculiar to the stomach and if  there is any 
difference in the aneuploidy level in different part of the gastro intestinal 
system. This may help to explain the difference in the incidence of cancers in 
different parts of the gastrointestinal system.
7. MAD2 and BUB1 gene expression levels have been studied here but it would 
be interesting to study other mitotic check point genes like Aurora Kinase A 
and Aurora Kinase B in the remaining RNA samples. Aurora KinaseA and B 
play an important role in the spindle check point regulation (Murata-Hori et al
2002). It has been shown that aurora kinaseB is essential for MAD2 and 
BUBR1 to attach to the kinetochore (Lens S et al 2010). There is a significant 
amount of research in determining the role of Aurora kinase inhibitors in the 
treatment of cancers.
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Appendices
Appendix 1.1
ANEUPLOIDY AND GENE TRANSCRIPTION LEVELS IN OESOPHAGEAL 
AND GASTRIC CANCERS.
REF 07/WMW01/46 VERSION 2
29/09/07
DR.A.SOMASEKAR, SPECIALIST REGISTRAR,
DEPARTMENT OF GASTROENTEROLOGY, NEATH PORT TALBOT 
HOSPITAL
WHY HAVE I BEEN ASKED TO PARTICIPATE IN THE STUDY?
You are waiting for a procedure called endoscopy, which is a magic eye test looking at 
the gullet and stomach. There are a lot of reasons why someone will have this procedure 
For example, heartburn, indigestion, abdominal pain, weight loss. All patients who are 
waiting for this procedure are invited to participate in the study .We are interested in a 
certain group of patients who might have inflammation of the gullet or stomach and we 
plan to study the inflammation in detail.
WHO ARE DOING THE STUDY?
The study is being performed by Dr. A.Somasekar, specialist registrar in 
gastroenterology and this study is supervised by Prof. J.G.Williams, Consultant 
Gastroenterologist at the Neath Port Talbot Hospital and Dr.G.Jenkins, Molecular 
Biologist at the Swansea University. Dr. A. Somasekar is carrying out this study for her 
research degree (M.D.,) at the Swansea University.
WHAT DOES THE STUDY LOOK AT?
The study aims to look at the lining of the stomach closely by taking biopsies and 
brushings from the lining of the stomach.
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HOW ARE THE BIOPSIES TAKEN AND BRUSHINGS TAKEN?
During the normal endoscopy we take 2-4 biopsies. They are not painful and you do not 
feel it. The cytology brushes are very small, flexible brushes and they are used to take 
scraping from the lining of the stomach and they are not painful procedures.
DOES IT EXTEND THE PROCEDURE TIME?
On an average the endoscopy takes approximately 15 minutes and if we take these 
additional biopsies the procedure time would be extended by another 4-5minutes.
ARE THERE ANY COMPLICATIONS WITH THE BIOPSIES?
Upper GI endoscopy with biopsies is generally a safe procedure and the complications 
are rare. Although it is safe procedure, there is a very small risk of bleeding or 
perforation that can occur during this procedure.
WHAT HAPPENS TO THE BIOPSIES AND BRUSHINGS TAKEN?
The biopsies are stored and analysed at the School of Medicine, Swansea. They would 
be looked at by a pathologist and certain proteins would be extracted from them to help 
us understand how this disease occurs. The cells from the brushes would be collected 
and will also be analysed for any abnormalities at the school of medicine.
WHAT HAPPENS TO THE EXTRA SPECIMEN?
The specimen would be stored during the study period and would be destroyed after 
this.
WHAT IF I DO NOT WANT TO PARTICIPATE IN THE STUDY?
If you choose not to participate in the study, this will not affect your procedure today or 
your future treatment.
WHAT IS THE BENEFIT TO ME BY THIS STUDY?
175
This study would help us in better understanding of the disease process which affects a 
significant percentage of the population but is unlikely to influence any of the treatment 
you are on at the moment.
WILL THE RESEARCH DIRECTLY AFFECT ME?
As this is a research looking at the progress of certain inflammatory condition, there is 
no need to worry regarding the results of the research as this study is aimed at 
improving our understanding of the disease and would not result in any change in your 
management at present.
WHAT WILL HAPPEN TO MY PERSONAL DETAILS?
These information would be stored in the hospital and only the research team would be 
eligible to access it. The biopsies and the brushings are coded so it does not bear any of 
your personal details.
WHO SHOULD I CONTACT TO DISCUSS REGARDING THE PROCEDURE 
AND TO GET THE RESULTS?
You can contact the endoscopy department on our direct line 01639 862037 or contact 
our specialist nurse on 01639 862551.
WOULD I BE ABLE TO OBTAIN THE RESULTS OF THE STUDY?
Yes, once the study is completed we plan to exhibit a poster with the results of the study 
in the endoscopy department at the Neath Port Talbot Hospital.
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Appendix 1.2
ANEUPLOIDY AND GENE TRANSCRIPTION LEVELS IN OESOPHAGEAL 
AND GASTRIC CANCERS
Neath Port Talbot Hospital
PATIENT CONSENT FORM
I have read the patient information leaflet and received a verbal explanation of the 
proposed research project.
I consent to additional biopsies and brushing during the endosopic procedure for research 
purposes.
I understand and agree that the information regarding me will be held at the hospital and 
the information I give will not be communicated to anyone outside the research team .
PATIENTS NAME
PATIENTS SIGNATURE DATE
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Appendixl.3
23/08/2007
ANEUPLOIDY AND GENE TRANSCRIPTION LEVELS IN OESOPHAGEAL AND 
GASTRIC CANCERS
Dr. A. S om aseka r ,  G a s tro e n te ro lo g y  Registrar, N ea th  Port Talbot Hospital. 
QUESTIONNAIRE
1.NAME
2. AGE
3. SEX
4. HOSP NO/DOB
5.WEIGHT
6 .EMPLOYMENT
7.SMOKING- DURATION/AMOUNT
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8. ALCOHOL -  UNITS/WEEK
9. DIET
10. PMH OF PEPTIC ULCER DISEASE/GI /OTHER CANCERS
11. F/H Gl CANCERS
12. PREVIOUS OGD
13. ENDOSCOPIC FINDINGS (CURRENT)
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Appendix 1.2
Raw data for the endoscopy brushings for chromosome 1:
Patient
Number 2Signal 1 Signal 3 Signal >3 Signal
1 193 4 2 0
2 151 3 3 3
3 105 3 3 1
4 194 8 0 1
5 259 8 2 2
6 209 7 3 2
7 183 5 0 0
8 252 8 1 3
9 351 13 1 1
10 347 7 1 1
11 256 19 1 5
12 214 10 1 0
13 402 3 1 2
14 391 8 3 3
15 500 9 2 7
16 120 5 0 0
17 222 5 0 1
18 149 7 0 4
19 145 3 3 0
20 299 3 2 0
21 141 6 2 1
22 131 3 0 1
23 65 3 0 0
24 255 8 0 3
25 231 2 1 1
26 266 2 3 1
27 129 4 0 0
28 244 14 0 1
29 232 7 1 0
30 133 4 0 1
31 255 3 2 0
32 243 2 1 1
33 243 2 1 1
34 105 1 0 1
35 193 0 3 3
36 248 8 4 0
37 263 4 1 0
38 75 0 1 0
39 94 2 0 0
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40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
148
231
214
49
62
315
305
91
97
213
235 10
59
367
247
327
217
214
244
211
102
435 23
141
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Appendix 1.3
Raw Data with Patients with Gastritis
Patients MAD2(A) MAD2(B) Mean
MAD2
SD for 
MAD2
BUB 1(a) BUB 1(B) Mean
BUB1
SD for 
BUB1
A4 7.500000 0.236000 3.870000 5.139939 0.723000 0.066500 0.723000 0.464396
A7 0.914000 0.162000 0.538000 0.531748 0.704000 0.171000 0.438000 0.376756
A8 0.929000 0.084100 0.506000 0.597140 0.348000 0.106000 0.227000 0.170910
A18 1.110000 1.110000 1.110000 0.000000 0.301000 0.301000 0.301000 0.000000
A20 3.340000 4.470000 3.910000 0.799362 1.130000 3.200000 2.170000 1.464597
A26 0.539000 3.750000 2.140000 2.267658 1.750000 1.460000 1.600000 0.204882
A32 0.533000 0.293000 0.413000 0.169631 0.185000 0.256000 0.221000 0.050586
A3 8 0.855000 0.855000 0.855000 0.000000 0.197000 0.197000 0.197000 0.000000
A39 1.090000 1.090000 1.090000 0.000000 0.258000 0.258000 0.258000 0.000000
A43 0.849000 0.904000 0.876000 0.038770 0.316000 0.267000 0.291000 0.035223
A56 0.402000 0.402000 0.402000 0.000000 0.133000 0.133000 0.133000 0.000000
A57 0.354000 0.354000 0.354000 0.000000 0.201000 0.201000 0.201000 0.000000
A62 2.090000 1.080000 1.580000 0.710276 0.316000 0.441000 0.379000 0.088658
A63 1.010000 0.738000 0.876000 0.193944 0.311000 0.361000 0.336000 0.035685
A72 0.906000 0.761000 0.833000 0.102570 0.215000 0.352000 0.284000 0.096602
A74 0.840000 0.761000 0.801000 0.056044 0.274000 0.253000 0.263000 0.014473
A75 0.810000 0.341000 0.575000 0.331711 0.374000 0.218000 0.296000 0.110327
A76 0.529000 0.656000 0.592000 0.089606 0.252000 0.196000 0.224000 0.038961
A77 1.030000 1.020000 1.030000 0.011341 0.510000 0.271000 0.391000 0.169122
A81 1.970000 0.826000 1.400000 0.807197 1.710000 0.419000 1.060000 0.910909
A78 1.640000 0.782000 1.210000 0.609824 0.405000 0.214000 0.310000 0.135400
A18 1.110000 1.110000 1.110000 0.000000
0.301000 0.301000
0.301000 0.000000
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Appendix 1.4
Raw data for patients with H. pylori associated gastritis
Patient MAD2(A) MAD2(B) Mean
MAD2
SD for 
MAD2
BUB 1(A) BUB 1(B) Mean
BUB1
SD for 
BUB1
A25 0.603000 1.690000 1.150000 0.767999 0.202000 0.215000 0.208000 0.009439
A36 1.110000 1.110000 1.110000 0.000000 0.631000 0.631000 0.631000 0.000000
A41 1.590000 1.020000 1.310000 0.402698 0.157000 0.226000 0.191000 0.048864
A54 0.857000 0.495000 0.676000 0.256129 0.608000 0.793000 0.700000 0.130464
A59 0.579000 0.579000 0.579000 0.000000 0.285000 0.285000 0.285000 0.000000
A73 0.860000 0.893000 0.877000 0.023017 0.709000 0.342000 0.526000 0.259694
A68 0.771000 1.580000 1.170000 0.571765 0.302000 0.302000 0.302000 0.000014
A35 10.900000 10.900000 1.090000 0.000000 1.450000 1.450000 1.450000 0.000000
Appendix 1.5
Raw data for patients with intestinal metaplasia
Patients MAD(A) MAD2(B) Mean
MAD2
SD for 
MAD2
BUB 1(A) BUB (B) Mean
BUB1
SD for 
BUB1
A61 1.260000 0.898000 1.080000 0.253637 0.462000 0.404000 0.404000 0.041001
A79 1.150000 0.914000 1.030000 0.165499 0.562000 0.563000 0.563000 0.000759
A80 0.585000 0.595000 0.590000 0.006865 0.292000 0.267000 0.267000 0.017652
A58 0.672000 0.512000 0.592000 0.112634 0.137000 0.596000 0.596000 0.324408
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Appendix 1.6
Raw Data for MAD2 and BUB1 expression levels
Patient Histology MAD2(A) MAD2(B) Mean
MAD2
SD for 
MAD2
BUB1
(A)
BUB 1(B) Mean
BUB1
SD for 
BUB1
A5 Normal 2.179395 0.117541 1.148468 1.457951 0.299899 0.035745 0.167822 0.186785
A6 Normal 1.370909 0.065676 0.718292 0.922939 0.142079 0.05105 0.096565 0.064368
A l l Normal 0.53885 0.760475 0.649662 0.156713 0.252044 0.202372 0.227208 0.035123
A31 Normal 0.985646 0.587368 0.786507 0.281625 0.316752 0.480008 0.39838 0.11544
A33 Normal 1.149702 1.149702 1.149702 0 0.398521 0.398521 0.398521 0
A42 Normal 0.747108 0.700082 0.723595 0.033252 0.235949 0.180267 0.208108 0.039374
A46 Normal 0.405171 0.475569 0.44037 0.049778 0.116853 0.179821 0.148337 0.044525
A69 Normal 0.825936 0.825936 0.825936 0 0.567173 0.567173 0.567173 0
A67 Normal 0.573357 0.491339 0.532348 0.057996 0.319321 0.302282 0.310801 0.012048
A70 Normal 0.372005 0.372005 0.372005 0 0.208027 0.208027 0.208027 0
A12 Normal 0.673833 0.040699 0.357266 0.447693 0.200476 0.042205 0.12134 0.111915
A14 Normal 10.95467 10.95467 10.95467 0 14.99323 14.99323 14.99323 0
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